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ABSTRACT
CRYPTOPHANE DERIVATIVES AS GAS SENSORS AND HYPERPOLARIZED
XENON-129 BIOSENSORS

Najat S. Khan
Professor Ivan J. Dmochowski

This thesis describes the progress in the development of cryptophanes for three
different applications: encapsulation of noble gases,

129

Xe NMR biosensing for cancer

detection, and the construction of molecular devices. A new water-soluble organic host
molecule, tris-(triazole ethylamine) cryptophane, was synthesized for noble gas detection.
This host was found to bind xenon with the highest affinity to date (KA = 42,000 ± 2,000
M-1 at 293 K). The same host was employed in the development of a radiometric assay
for measuring the association constant of radon binding to a discrete molecular species,
KA = 49,000 ± 12,000 M-1 at 293 K. For cancer detection by hyperpolarized 129Xe MRI, a
new folate-conjugated cryptophane biosensor was developed that targets folate receptors
(FR) overexpressed in a majority of cancer cells. The biosensor was relatively non-toxic
at low micromolar concentrations required for imaging and was shown to selectively
target cancer cells overexpressing FR. Flow cytometry results indicated a 10-fold higher
cellular internalization in KB cells (FR+) than in HT-1080 cells (FR-). Finally, a smaller
cavity tribenzylamine hemicryptophane was synthesized where the molecular structure
and motions of the cage closely resembled that of molecular gyroscopes. It also provided
a vehicle for exploring the structure and properties of multiple p-phenylene rotators
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within one molecule. The compact size and molecular motions of this gyroscope-inspired
tribenzylamine hemicryptophane make it an attractive starting point for controlling the
direction and coupling of rotators within molecular systems.
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CHAPTER 1: INTRODUCTION
1.1. The role of cryptophanes in host-guest chemistry

Host-guest chemistry involves the encapsulation of neutral and charged species by
a variety of synthetic molecular systems.1 This host-guest association is a key aspect of
many applications in chemistry and biochemistry and has helped to elucidate many of the
fundamentals of molecular recognition2-9 and complexation among biological systems in
Nature.10-16 One of the first model studies of molecular recognition involved the binding
of ammonium ions by crown ethers in solution by Pederson et al.17 Since then, there has
been a rapid growth in the synthesis of various organic hosts and investigation of their
binding to guest molecules. Examples of organic synthetic host molecules include
calixarenes,18-22 cavitands,23 cyclodextrins,24,25 crown ethers,24,25 carcerands,26 and
cryptophanes.1 Due to the different molecular structures of these hosts, a wide variety of
cavities with guest-binding properties are present, which has led to applications in drug
delivery,27 molecular recognition,23 storage and separation,28 and catalysis.29-31

Cryptophane-A is a molecular cage that was first developed by André Collet in
1981.32,33 Since then, extensive research has been performed with this cage and its
derivatives in the field of host-guest chemistry.1 It is a chiral molecule with D3 symmetry,
which is formed when two CTV (cyclotriveratrylene) units are joined by three ethylene
linkers (Figure 1.1). Guests are encapsulated within the cavity due to the presence of the
three portals in the equatorial region of the cage. Previous work has shown that the size
1

and nature of the cavity can be tuned by varying the molecular structure as well as the
length of the linkers.34 The internal volume has been estimated to be 87 Å3 (Figure 1.1),
based on high-resolution X-ray crystallographic studies.35,36 Cryptophane-A has been
shown to reversibly bind to a variety of neutral small molecules (e.g. methane, KA = 130
M-1 in C2D2Cl4 at 298 K; chloroform, KA = 230 M-1 in C2D2Cl4 at 298 K; and xenon, KA
= 3900 M-1 in C2D2Cl4 at 278 K).37,38
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Figure 1.1. Cryptophane-A
Structure of Cryptophane-A.
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High-resolution X-ray structures of cryptophane-A and trifunctionalized derivative
complexes have been reported with water, methanol, xenon and chloroform in the
Dmochowski group.36 In the case of methanol and xenon, the cavity is underfilled with a
packing coefficient (defined as guest volume divided by host internal volume) of 0.39
and 0.47 respectively, whereas it is overfilled with chloroform as the guest (0.73).36
According to Rebek’s “55% rule”, the volume of the guest and host are both critical for
encapsulation processes to occur. By studying a variety of host-guest complexes they
were able to determine that optimal binding is reached when the packing coefficient is
0.55 ± 0.09 in organic liquids.35 It is therefore not surprising that xenon binds with the
highest affinity to cryptophane since the packing coefficient at 0.47 is closest to the
empirically determined value reported by Rebek et al. This is also supported by the fact
that X-ray structures indicated nearly optimized van der Waals interactions between
xenon and the six cyclotriguaiacylene (CTG) phenyl moieties (experimental average =
4.31 Å, optimal van der Waals interaction distance for Xe and phenyl carbon is 3.86 Å).36
In order to accommodate guests of different sizes, the crystal structures indicate that the
trifunctionalized cryptophanes are able to increase the internal cavity volume by more
than 20% by the expansion of two of the three ethylene linkers (Figure 1.2).36 This study
provided the first example of xenon-cryptophane association in the solid state and further
demonstrated the role of cryptophanes as organic hosts that are capable of undergoing
‘induced fit’ to optimize binding via London forces to guest molecules.

4

Figure 1.2. Side view of two superimposed crystal structures of a cryptophane-A
derivative, triallyl cryptophane. The cryptophane is shown encapsulating MeOH (grey)
and CDCl3 (pink). Guests, hydrogens and side chains were removed for easier viewing.
Figure adapted from Taratula et al.36
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In order to eventually perform in vivo studies, water-soluble versions of
cryptophane-A have also been synthesized: Huber’s hexa-acid cryptophanes (KA = 6,800
M-1 at 293 K) where the six methoxy groups were replaced by -OCH2CO2H groups,39
tris-(triazole propionic acid) cryptophane (TTPC) (KA = 17,000 M-1 at 293 K),40 and
triacetate-functionalized cryptophane (TAAC) (KA = 33,000 M-1 at 293 K) (Figure 1.3).41
The binding of xenon to TTPC and TAAC was measured by isothermal titration
calorimetry (ITC) and fluorescence quenching.40,41 TAAC has three carboxylate groups
close to the cryptophane core and was determined to have the highest binding affinity for
xenon of any host molecule in buffer.41 The higher binding affinity in aqueous buffer
compared to organic solvents is due to the higher enthalpic and entropic contributions in
buffer. The higher enthalpic contributions arise from increased van der Waals interactions
due to a more compact shape in water (assisted by the flexible ethylene linkers) whereas
the desolvation of the water shell around xenon upon binding to cryptophane accounts for
the high entropic contribution (Figure 1.3).40,41
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Figure 1.2. Huber’s Hexa-acid Cryptophanes.

Figure 1.3. Water-soluble cryptophanes a) Huber’s hexa-acid cryptophanes, b) TAAC

A.) Huber et al. synthesized a series of water-soluble cryptophanes that differed

and TTPC,
c) A major
contributor
to xenon
binding
in the length of the dioxy
alkane bridges.
B.) Chemical
shifts moved
upfield

is entropy which arises from the

about 30 ppm with increasing cavity size from about 65 ppm for the smallest

desolvation of Xe. Roughly 20 water molecules make up the first solvation sphere of the

cryptophane to about 35 ppm for the largest cryptophane. Figure adapted from
Huber et al.35

Xe atom in aqueous solution. Figure adapted from Huber and Hill, et al.39-41
10

7

This thesis outlines the synthesis and development of a new water-soluble aminebased cryptophane-A derivative with the goals of expanding the variety of neutral
molecules reversibly binding to cryptophanes and determining the substituent effects on
xenon binding affinity. The binding of radon and xenon to this molecule was
investigated. Although both radon and xenon are noble gases, unlike xenon, all 35
isotopes of radon are radioactive. Radon is formed as an intermediate species resulting
from the decay of uranium-238, which is found in the Earth’s crust. It is considered to be
an indoor air pollutant since exposure to radon (due to high levels of accumulation within
homes) leads to the incidence of lung cancers in many geographic regions.42 Despite this,
there is currently no literature data for the binding of radon to a discrete molecular
species. So far, only the adsorption of radon to bulk substrates such as charcoal, silica gel
and ice,43 and on the formation of radon halides44 has been determined. Therefore, a
novel sensitive assay was developed in the Dmochowski lab to determine the binding of
radon to cryptophane. Additionally, the binding of xenon to the same host was also
investigated using isothermal titration calorimetry (ITC).

8

1.2. Development of targeted 129Xe biosensors

Among the small, neutral molecules that are reversibly encapsulated by
cryptophanes, xenon has garnered the most attention. This is because of the promising
potential of using hyperpolarized (hp)

129

Xe biosensors as novel contrast agents for

magnetic resonance imaging (MRI) and spectroscopy (MRS).45 Although MRI is one of
the most widely used non-invasive tools for imaging deep tissues with high spatial and
temporal resolution (with approximately 30 million procedures performed per year in the
U.S.), it suffers from several limitations. Because the intrinsic signals are from protons in
water and fat, there is usually low sensitivity and high background noise present. Lungs
are difficult to image due to low proton concentration whereas in the brain, multiple lipid
bilayers decrease sensitivity due to high proton noise, resulting in poor signal-to-noise
ratios.46,47 As a result, several small tumors may remain undetected until they have
progressed and become larger, which then may hurt patient prognosis. To overcome this
problem, MRI contrast agents are currently used to increase the signal-to-noise ratio and
include gadolinium chelates,48-50 iron oxide nanoparticles51-54 and manganese chelates.55
Contrast agents are generally paramagnetic species that increase signal-to-noise ratio by
changing the longitudinal (T1) or transverse (T2) relaxation times of neighboring water
molecules. Gadolinium contrast agents (e.g. Omniscan) are most frequently used and
account for 40-50% of MRI scans.49 Although they do improve the contrast of MRI
images, they are not targeted towards specific biomarkers. Since they depend on relative
changes for imaging, Gd contrast agents are less effective at multiplexing and detecting
proteins at low concentrations.56,57 Additionally, U.S. and European agencies have issued

9

advisories against Gd agents based on the toxicity risks posed to patients with impaired
renal function who may develop nephrogenic systemic ﬁbrosis/nephrogenic ﬁbrosing
dermopathy (NSF/NFD).58 This disease has recently “disappeared”, due to greater
awareness

of

NSF

and

the

risks

posed

to

the

dialysis

patient population. Other contrast agents include iron oxide nanoparticles, which are
effective at imaging liver lesions, but are plagued by low sensitivity due to small changes
in T2.54 Manganese chelates are also used but tend to accumulate in the liver and have
low sensitivity due to small changes in T1.55 As a result of low sensitivity and toxicity
concerns, alternative nonproton-based, hyperpolarized MRI agents such as
83

129

Xe,

13

C,

Kr and 3He are currently being explored.59-62

129

Xe is an attractive MRI contrast agent since it is spin-½ (26.5% isotopic

abundance), non-toxic, inert (below its anesthetic threshold, which is 70% by volume of
inhaled gas mixtures), has millimolar solubility (~5 mM) in water63 and is very
polarizable. The polarizability of the 56 electron cloud is reflected by the large chemical
shift window (> 300 ppm).64 This allows for the simultaneous detection of different
species (i.e., multiplexing), which is currently not possible with untargeted 1H MRI
contrast agents. Since most diseases lead to overexpression of a variety of biomarkers,
the ability to perform multiplexed detection through MRI would greatly increase the
effectiveness and sensitivity of this imaging modality. Additionally, hp

129

Xe can be

generated through spin-exchange optical pumping (SEOP) to increase NMR signal by
more than 10,000-fold. This helps to increase the sensitivity of MRI.65 SEOP polarizes
129

Xe gas by transferring angular momentum from circularly polarized light to rubidium.
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The nuclear spin from polarized rubidium is then transferred to the nuclear spin of xenon
through dipolar coupling (Figure 1.4a). As a result, a > 10,000-fold signal enhancement is
achieved relative to the normal Boltzmann distribution of nuclear spins.65,66 The
hyperpolarized state has a spin–lattice relaxation time T1 of roughly 70 min.67 However,
the T1 value is significantly reduced in the present of paramagnetic species such as iron
and oxygen. As a result, the T1 value is only 4 seconds in deoxygenated blood and 13
seconds in oxygenated blood.68 Despite this, several in vivo MRI imaging studies with hp
129

Xe gas have already been performed. In cases where

129

Xe gas was introduced via

inhalation, organs such as the brain and lungs were successfully imaged.47,69-76 It has also
been possible to image organs by introducing 129Xe via direct intravenous77 and arterial71
routes in rodents. Additionally, since it is now possible to deliver over 50% hp
ﬂow rates of 1–2 L/min, the potential for performing MRI where hp

129

129

Xe at

Xe gas is

continuously replenished via inhalation has further increased.78,79 This would allow for
organs such as the brain and the lungs to be imaged over extended periods of time. It has
also been reported that the hyperpolarized lifetime of xenon can be increased to 20-30
seconds by co-injecting with intralipids or emulsions, which may allow for the possibility
to image a wider variety of organs.71,80
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Figure 1

Figure 1.4. a) The process of spin-exchange optical pumping to produce hp 129Xe gas, b)

(A) Process of optical pumping to produce hyperpolarized 129Xe. (B) Schematic representation of hp 129Xe NMR spectrum showing (from left)
resonances of free xenon gas in aqueous solution, Xe-encapsulated biosensor bound to corresponding bioreceptor, and Xe encapsulated in free
129
biosensor. Legend shows components of biosensor: molecular cage, linker, and recognition moiety.

Schematic representation illustrating the primary concept of
whereby there is a distinct shift in

129

Xe NMR biosensing

Xe NMR resonance upon binding to the targeted

Owing to its filled valence electron shell, xenon resists
3-carbon spacers, xenon affinity decreases with increasing
forming covalent bonds; nonetheless, it shows modest
size of the cavity [24].
biomarker.
Adapted
fromorganic
Taratula et al.45
affinity for hydrophobic
cavities found
in many
molecules [16–19]. For example, the association conCryptophane-1,1,1 was recently synthesized [25#] and
!1
for hemicarcerands [20] and
exhibits the highest Xe association constant measured
stant, KA, is 200 M
20 M!1 for a-cyclodextrin [17]. A calix[4]arene derivain organic solvent, KA = 10 000 M!1 at 293 K. This host
tive exhibited a KA of only "14 M!1 at 298 K in water
has a calculated internal volume of 81 Å3, making the
[21] whereas for water-soluble cucurbit[6]uril, a xenon
xenon volume (42 Å3) to host ratio equal to 0.52, which is
!1
very close to Mecozzi and Rebek’s prescribed 0.55 ratio
binding constant of 3000 M was measured [18]. In
fact, the non-covalent, dynamic association of 129Xe
for non-polar host–guest complexes mediated purely by
with these host molecules creates opportunities for
London forces [26]. Cryptophane-1,1,1 shows very slow
xenon biosensing applications, as xenon can be hyperdecomplexation kinetics, which not only produces a
polarized separately as the gas and subsequently intronarrow 129Xe NMR resonance useful for direct detection,
but also hinders the Xe exchange needed for indirect
duced to the host molecule, at multiple time points for
detection [27##]. As this example shows, both thermolongitudinal studies.
dynamics and kinetics impact the design of host molecules for xenon-biosensing applications.
Cryptophane-A, first reported in 1981 [22], is the most
studied Xe-binding cage and is composed of two cycloSeveral water-soluble cryptophanes have been synthestriveratrylene caps joined by three ethyl linkers, which
ized to date, many with exceptional xenon-binding
give an internal van der Waals volume of approximately
´
characteristics [28,29,30#]. Huber’s water-soluble crypto95 Å3 (Figure 2). As a result of its connectivity, cryptophane-A has D3 symmetry and is chiral. Cryptophane-A is
phanes [28] replaced all six methoxy groups with OCH2COOH. The Xe affinity of hexa-acid cryptophane-A was
also commonly referred to as cryptophane-2,2,2, based on
measured to be 6800 M!1 at 293 K. Conformational
the three 2-carbon spacers. Cryptophane-A binds Xe
!1
in C2D2Cl4 at 278 K
changes were observed in the hexa-acid cryptophanes,
reversibly with KA "3900 M
[23]. In a series of related cryptophanes incorporating
including a non-xenon-binding crown-saddle isomer. Our
Current Opinion in Chemical Biology 2010, 14:97–104

www.sciencedirect.com
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In order to perform biosensing applications with water-soluble cryptophane-based
129

Xe contrast agents, two major strategies have been pursued: 1) localization of

129

Xe

signals at the desired target to enhance signal-to-noise and, 2) multiplexing, which would
allow for the simultaneous detection of various disease biomarkers.45,81 The first strategy
requires the synthesis of water-soluble cryptophane-A derivatives that bind tightly to
xenon. As mentioned earlier, our lab has worked extensively on developing high affinity
water-soluble cryptophane-A derivatives for in vivo applications where it is crucial for Xe
to bind preferentially to cryptophanes and outcompete other proteins and fatty tissues
present in the body. The binding affinity of Xe for proteins tends to be low and ranges
from 10 M-1 for hemoglobin to 200 M-1 for myoglobin82,83 whereas the affinity for watersoluble, tri-substituted cryptophanes synthesized in our lab ranges from 17,000 to 33,000
M-1 in buffer and 22,000 M-1 in blood plasma at 293 K.40,41

The second strategy of

multiplexing has also been developed in recent years where targeted cryptophane
biosensors have been synthesized by conjugating the host molecule with a ligand that
targets a biologically relevant biomarker (Figure 1.4b). The unbound biosensor has a
unique NMR resonance and upon binding to the biomarker, additional 129Xe NMR peaks
are formed that can be easily differentiated from the initial NMR resonance of the
unbound biosensor. If a large variety of such biosensors could be developed where each
targets a specific biosensor and had a unique chemical shift upon binding, a large number
of targets could be investigated simultaneously, thereby leading to a more sensitive and
accurate diagnosis.
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The first example of such a targeted

129

Xe biosensor consisted of a biotin-

conjugated cryptophane which gave a unique resonance at 70 ppm in solution.81 Upon
binding to streptavidin, a new peak was formed at ~72.5 ppm (Figure 1.5). Therefore, a
~2.5 ppm shift illustrates that the polarizable xenon atom is able to detect a difference in
the chemical environment upon binding.81 Since xenon has a large chemical shift
window, this proof-of-concept experiment indicated the potential of

129

Xe NMR

biosensors for multiplexing, whereby multiple biomarkers that indicate cancer formation
can be simultaneously detected using MRI. Following this example, our lab developed an
enzyme-responsive

129

Xe biosensor that targeted the enzyme matrix metalloproteinase-7

(MMP-7).84 MMP-7 is an important target since it is responsible for degrading
extracellular matrix and is highly upregulated near tumors of the colon and breast.85-87
Upon proteolysis of the peptide (MMP-7 substrate), two new NMR peaks (the biosensor
consisted of two diastereomers) were formed 0.3 and 0.5 ppm upfield from the uncleaved
NMR peak.84 Although the change in chemical shift was not very significant for in vivo
applications, this study illustrated that enzymatic activity can be detected by using

129

Xe

NMR biosensors. Larger chemical shifts differences (3.0 to 7.5 ppm) upon binding were
observed with a p-benzenesulfonamide-conjugated

129

Xe biosensor used to target

carbonic anhydrase isozymes I and II (Figure 1.6a, b).88 X-ray crystallography studies by
the Christianson lab confirmed the presence of one xenon atom in the cryptophane cage
as well as the binding of the benzenesulfonamide moiety in the carbonic anhydrase II
binding site (Figure 1.6c).89 It is also interesting to note that for the 6-bond linker moiety,
xenon was able to differentiate CA I from CA II (which have slightly different chemical
shifts) while for the 7-bond linker, xenon was not only able to distinguish between the
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two isozymes, but was also able to differentiate between the two diastereomers of the
biosensor when bound to CA II.88 Therefore, the sensitivity of these contrast agents
coupled with the significant chemical shift changes upon binding to biomarkers makes
them promising candidates for 129Xe NMR biosensing.
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A) Streptavidin biosensor. Cryptophane-A is conjugated to a biotin ligand

Figure 1.5. a) Biotin-conjugated 129Xe biosensor, b) Hp 129Xe NMR resonance for the
through
a PEG maleimide
linker. The Biosensor.
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Figure
1.3. Design
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A.) Cryptophane-A was functionalized with two propionic acid groups to confer
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Binding of the compounds (top row) to carbonic anhydrase I (middle row) and II
(bottom row) generated downfield shifts ranging from 2.5 to 7.5 ppm.

Figure 1.6. a) Chemical structure of a benzenesulfonamide-conjugated
13 cryptophane with
a variable length linker that targets CA, b)

129

Xe NMR spectroscopy showing the

biosensors binding to CA I and II, c) Crystal structure showing the binding of the C8B
biosensor to CAII where the Xe atom (green) is bound to cryptophane and the targeting
sulfonamidate anion is coordinated to Zn2+ (gray). Adapted from Aaron and Chambers, et
al.88,89
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In order to pursue biological applications with

129

Xe NMR biosensors, our lab

performed the first successful delivery of water-soluble cryptophanes to cancer and
normal cells by conjugating cryptophanes with cationic cell penetrating peptides which
are able to cross cell membranes.90-92 The cellular delivery of the cryptophanes was
confirmed by using confocal laser scanning microscopy. In order to target specific cancer
biomarkers, the next step involved conjugating cryptophanes with targeting moieties and
performing biological studies to determine cytotoxicity as well as the selectivity of
delivering these biosensors to cancer cells overexpressing the targeted biomarkers.

This thesis outlines the work done towards the development of a

129

Xe biosensor

to target the cancer biomarker, folate binding protein (FBP). FBP is a membrane-bound
glycosylphosphatidylinositol (GPI)-linked membrane glycoprotein, which is highly
upregulated (3-5 million copies/cell) in colon, breast, ovarian and brain tumors whereas it
is underexpressed in most normal tissues.93-96 It is upregulated in fast growing cancer
cells as folic acid, an essential component for one-carbon transfer reactions, has a high
affinity for FBP and is transported into cells via folate-receptor mediated endocytosis.
Previous studies have shown that FBP can effectively deliver folic acid-conjugated
nanoparticles and imaging agents into cells.94 In this thesis, a new water-soluble
cryptophane-A derivative was conjugated to a selectively protected (γ-conjugate) folate
moiety. Confocal laser scanning microscopy, flow cytometry, cytotoxicity assays and
hyperpolarized

129

Xe NMR spectroscopy were performed to determine cellular viability,

cellular delivery and the selectivity in delivering the biosensor to cancer cells
overexpressing FBP. These studies are crucial for the development of a library of targeted

18

cryptophane-based

129

Xe biosensors, each of which can be selectively delivered to the

desired biomarkers, thereby enabling in vivo multiplexing during MRI.
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1.3. Hemicryptophanes: a new application in the development of molecular devices

Related molecules to cryptophanes are hemicryptophanes, where one of the two
CTV units is replaced by a N, O, S, or P atom to add different functionalities into the
cage. As a result, the internal cavity tends to be dissymmetric.97 Hemicryptophanes have
found a wide range of applications as organic hosts, metalloreceptors and catalysts.
Recent examples of hemicryptophanes include the synthesis of chiral trialkanolaminebased hemicryptophanes, which can act as metalloreceptors by forming an oxovanadium
complex.98 Another type of hemicryptophane modified with a thiophosphorylated group
has been confirmed by crystallographic analysis to encapsulate toluene.97 Additionally,
the Ugi-type multi-component macrocyclization reaction was employed to synthesize
diverse hemicryptophanes by using polyfunctional building blocks.99 Zn(II)–included
hemicryptophane has also been shown to have significant catalytic activity in the
hydrolysis of methyl para-nitrocarbonate.100 Triamide hemicryptophanes have also
shown strong affinity for ion-pairs due to their heteroditopic character.101

This thesis outlines a potentially new application for hemicryptophanes in the
field of molecular devices and components. In recent years, there has been an explosive
growth in the development of chemical systems that rely on electronic, chemical or
mechanical effects to mimic the functions of macroscopic devices.102 These systems have
not only allowed for the development of molecular-level machines,102 but also have
provided a platform for understanding complex biological machines, e.g. bacterial
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flagella, ATPase pumps, etc.

103-110

Examples of such molecular mechanical systems

include brakes, gears, propellers, turnstiles, and gyroscopes (Figure 1.7).105,111-114

21

Figure 1.7. Examples of molecular devices and components that rely on chemical,
electronic and structural changes to mimic macroscopic devices. a) Mislow and
Iwamura’s “molecular bevel gears”,113 b) Stoddart’s “shuttles”,115 c) Moore’s “molecular
turnstiles”,116 d) Kelly’s “brakes”,117 and e) Feringa’s photochemically driven
“motors”.118 Figure adapted from Khuong et al.119
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In this thesis, a novel hemicryptophane was designed where one of the two CTV
units was replaced by a tribenzylamine moiety. Although the new hemicrptophane was
originally developed for host-guest applications, binding experiments revealed that the
three rotating phenylene groups in the cage prevented the binding of small gaseous guests
and solvent molecules at standard conditions. Upon further investigation, it was
determined that the molecular structure and motions of this hemicryptophane closely
resembled that of molecular gyroscopes. The criteria of designing molecular gyroscopes
include rotary elements (rotators) that are connected to a static framework (stator).
Among the several molecular gyroscopes that have been previously synthesized, one
example consists of using metal-centered motifs to create gyroscopes where the central
rotator is protected by a three-spoke stator.102,120-124 Another example includes the
synthesis of amphidynamic crystals by Garcia-Garibay and coworkers where the central
rotator of a solid-state gyroscope is protected by bulky substituents that form the
stator.125-134 In both cases the rotator is protected by the stator to allow for low-barrier
rotation. Yet due to the intercalation of solvent molecules or steric effects in solid-state
studies, these gyroscopes have encountered undesirable barriers to rotation. Therefore, in
this thesis we outline the design of a novel hemicryptophane, which unlike previous
examples, has multiple, proximate rotators within one molecular system with an internal
cavity small enough to deter the inclusion of solvent and gaseous molecules that could
hamper rotation of the rotators. Also, we investigated the rate of rotation by 1H variable
temperature (VT) NMR spectroscopy and molecular dynamics (MD) simulations. The
results outlined in this thesis indicate that hemicryptophanes make for compelling initial
motifs for the synthesis of future molecular gyroscopes where the rotation could be
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controlled in a unidirectional fashion by incorporating either bulky substituents or dipole
moments in the rotators.
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ABSTRACT
Xenon and radon have many similar properties, a difference being that all 35
isotopes of radon (195Rn through

229

Rn) are radioactive. Radon is a pervasive indoor air

pollutant believed to cause significant incidence of lung cancer in many geographic
regions, yet radon affinity for a discrete molecular species has never been determined.
By comparison, the chemistry of xenon has been widely studied and applied in science
and technology. Here, both noble gases were found to bind with exceptional affinity to
tris-(triazole ethylamine) cryptophane, a new water-soluble organic host molecule. The
cryptophane-xenon association constant, KA = 42,000 ± 2,000 M-1 at 293 K, was
determined by isothermal titration calorimetry. This represents the highest measured
xenon affinity for a host molecule. The partitioning of radon between air and aqueous
cryptophane solutions of varying concentration was determined radiometrically to give
the cryptophane-radon association constant: KA = 49,000 ± 12,000 M-1 at 293 K.
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INTRODUCTION
Radon and xenon were isolated by Ramsay and co-workers more than one century
ago, but since that time only the chemistry of xenon has received much attention. Xenon
can be harvested from the atmosphere and has wide-ranging applications, from plasma
televisions to ion propulsion systems for spacecraft. Radioactive 133Xe is used as a tracer
for measuring physiological blood flow1 and also in detecting long-range fallout from
nuclear weapons testing.2 Stable isotope

129

Xe has a spin-½ nucleus that can be

hyperpolarized to generate very large signals for magnetic resonance imaging (MRI).3
Host molecules have been identified that bind xenon with high affinity,4 motivating
further technological applications. Much less studied is radon, a radioactive noble gas
that occurs as an intermediate species in the decay chain of uranium-238, an element
ubiquitous in Earth’s crust. Epidemiological studies indicate that indoor accumulation of
radon may cause a 5-31% increase in lung cancer risk per 100 Bq m-3 exposure.5 In
Europe, such a level corresponds to 2% of all cancer deaths.5 The imperative to detect
and remediate indoor radon motivates the study of radon chemistry, as do other scientific
applications such as radon emission related to seismic activity.6 Prior radon-chemical
studies have focused on adsorption of the gas to bulk substrates7 such as charcoal, silica
gel and ice, and on the formation of radon halides.8 Radon hydrates have also been found
to incorporate into the crystal lattices of SO2 and H2S hydrates.8 Until now, no discrete
molecular species has been shown to bind radon, presenting an exciting frontier in noble
gas research and host-guest chemistry.
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Radon is 10-15% larger by van der Waals volume than xenon (VXe ≈ 42 Å3, VRn ≈
47 Å3)9 and exhibits higher polarizability (αXe = 4.044 Å3, αRn = 5.3 Å3),10 which should
promote binding to void spaces. These observations led us to examine binding of radon to
a cryptophane organic host molecule that has well established xenon affinity.4
Cryptophane-A, consisting of two cyclotriguaiacylene caps joined by three ethylene
linkers, has been shown to encapsulate xenon reversibly as a host-guest complex.11
Recent X-ray crystallographic studies have shown that the internal volume of
trisubstituted cryptophane-A derivatives can vary by more than 20%, depending on the
size of the encapsulated guest.12

Several cryptophane-A derivatives have been synthesized and shown by
isothermal titration calorimetry (ITC), fluorescence quenching and NMR studies to
exhibit xenon association constants as high as 33,000 ± 3,000 M-1 at 293 K in phosphatebuffered water (Figure 2.1).13-16 Herein, we report a new cryptophane-A derivative, tris(triazole ethylamine) cryptophane (TTEC), with superior xenon-binding characteristics.
A sensitive radiometric assay was developed for measuring radon binding to the same
cryptophane.
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Figure 2.1. Water-soluble cryptophanes tris-(triazole propionic acid) (TTPC) and
triacetic acid cryptophane-A (TAAC). Figure adapted from Hill, et al.15
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RESULTS AND DISCUSSION

Figure 2.2. Synthesis of tris-(triazole ethylamine) cryptophane-A (TTEC), top view
shown.
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Synthesis. The synthetic route leading to TTEC (compound 6) is outlined in Figure 2.2
and briefly described here. A list of reagents, general methods, and synthetic procedures
are provided in the Experimental procedures section. Tripropargyl cryptophane 4 was
synthesized in 10 steps in 4% overall yield according to literature procedure and matched
the reported physical constants and NMR spectrum.14 2-Azidoethylamine was
synthesized in 93% yield, also following literature precedent.17 Reaction of 4 with three
equivalents of 2-azidoethylamine was achieved via copper(I)-mediated [3 + 2] Huisgen
cycloaddition18-21 to give the water-soluble TTEC (6). TTEC was purified by HPLC
(Experimental procedures section provides representative trace) and isolated in 75%
yield. TTEC identity was confirmed by 1H,

13

C, and hyperpolarized

129

Xe NMR

spectroscopy (see Experimental procedures), in addition to matrix-assisted laser
desorption/ionization mass spectrometry.

42

Figure 2.3. Enthalpogram of xenon binding to TTEC. Saturated aqueous xenon solution
(5.05 mM) was titrated into 140 µM TTEC in phosphate buffer (20 mM, pH 7.5) at 293
K.
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Xenon Binding. To study the binding of xenon to TTEC, we utilized an ITC protocol
previously developed in our laboratory.14 The experiments were performed by titrating
TTEC in phosphate buffer (20 mM, pH 7.5) at 293 K with saturated xenon-in-water
solution (5.05 mM at 1 atm, determined from the literature).22 The association constant
was measured to be KA = 42,000 ± 2,000 M-1 at 293 K, which is the highest xenon
affinity measured for any synthetic or naturally occurring host molecule. The cited
uncertainty interval for KA is a standard uncertainty, assumed to correspond to a standard
deviation, whose principal component was the uncertainty of the enthalpogram fit.
Specifically, fitting of the enthalpogram (molar heat evolved vs. molar ratio, Figure 2.3)
yielded thermodynamic parameters for the encapsulation: ∆H = -14.96 ± 0.30 kJ mol-1; T∆S = -10.97 kJ mol-1 at 293 K. Note that enthalpic and entropic components contributed
similarly to the Gibbs free energy of xenon binding at 293 K (∆G = -25.93 kJ mol-1),
which is believed to incorporate contributions from the dissolution of the clathrate water
structure that surrounds xenon in solution, the release of one or more water molecules
from the cryptophane cavity, and the non-covalent dispersion interactions between bound
xenon and TTEC.
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Figure 2.4. Diagrammatic representation of the radon binding affinity measurement,
which exploits the partition of radon between aqueous and gaseous phases. ‘LS’ refers to
liquid scintillation counting. L is the Ostwald coefficient of gas partition and KA is the
radon association constant to be determined.
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Radon Binding. Studies of radon binding used 222Rn evolved from the decay of 226Ra in
four capsules, akin to NIST standards disseminated as SRM 4973
polyethylene-encapsulated

226

23

and consisting of

Ra solution. These capsules generate a radium-free radon

solution from decay of the radium and diffusion of the gaseous radon out of the
capsules,24 and have been used to produce very small quantities of radon for use in
calibrating environmental standards, e.g. those of drinking water. In particular, only
about two femtomoles of radon were available for use in our studies, rendering
impractical the fluorescence quenching and ITC methods we previously used to measure
xenon binding to cryptophane in water.14 Instead, we devised a method (Figure 2.4)
wherein the binding of radon to TTEC could be measured radiometrically by liquid
scintillation, a technique with detection efficiency approaching five due to equilibrated
radon progeny.25 A related technique, involving gas-phase activity measurement, has
been used to determine the partition of radon between water and various organic
liquids.26 Radon partitions between gas and liquid phases according to a known ratio: the
Ostwald solubility coefficient27 (L) for that liquid and temperature.

Cryptophane

dissolved into the liquid phase of such a system acts as a radon sink and perturbs the
system away from the Ostwald value in proportion to the binding affinity. Thirty to forty
minutes were allowed for radon to partition between the gas and liquid phases, with
intermittent mixing. Subsequent sampling of the liquid phase allowed determination of
the “apparent partition coefficient”, and from that KA. We begin with the standard
expression of KA:
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KA =

[Bound]
.
[TTEC ] free [ Rn] free

Because [Rn] << [TTEC] (femtomole vs. micromole quantities), the simplification was
made that [TTEC]free ≈ [TTEC]. Therefore,
KA =

AB
1
A free [TTEC]

where AB and Afree are the bound and free radon activities in solution, which were not
!

independently measured. We have the definition of the Ostwald partition coefficient,
L=

[Rn] free
A freeVg
=
,
[Rn]g
AgVl

where Vg and Vl are the gas and liquid phase volumes and Ag the gas-phase radon activity.
€

Defining the apparent partition coefficient, Lʹ′

L! =

(A free + AB )Vg
,
AgVl

we arrive at the relationship,

Lʹ′ = LK A[TTEC] + L.
(1)
From LS counting before and after exposure to cryptophane, we determined Ag and (Afree
+ AB), which in turn yielded Lʹ′. Our Lʹ′ vs. [TTEC] data were fit by linear regression to
equation (1) (Figure 2.5). By this method, the affinity of TTEC for radon was found to
be KA = 49,000 ± 12,000 M-1 at 293 K. The standard uncertainty given here for KA
derived from the 95% confidence intervals on the parameters of fit to the apparent
partition coefficients vs. TTEC concentration series (Equation 1 and Figure 2.5). The
47

uncertainty in the radon assays used to derive the partition coefficients was negligible.
These data were well fit by a linear model, with R2 = 0.87. Radon activity measured for
reaction vessels containing no cryptophane deviated from this line, as expected when the
[Rn] << [TTEC] condition no longer holds.
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Figure 2.5. Apparent partition coefficient, Lʹ′, as a function of cryptophane concentration.
The circles represent reaction vessels that contained no cryptophane; the squares
represent a series of increasing cryptophane concentrations in the non-saturated regime,
fitted to equation (1).
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From these experiments, radon was found to bind TTEC with a free energy of
binding 0.4 kJ/mol more negative than in the case of xenon (-26.3 vs. -25.9 kJ/mol).
However, radon is also more soluble in water solution than xenon and therefore liberates
less free energy upon desolvation (-20.71 kJ/mol, Rn vs. -23.18 kJ/mol, Xe; est.).28
Accounting for this, we estimate that supramolecular interactions of the TTEC-Rn
complex, e.g. balance of improved dispersion interactions and entropic cost of
confinement, produce a free energy of binding 2.9 kJ/mol stronger than in the TTEC-Xe
complex.

Our previous crystallographic study showed that the internal volume of

trisubstituted cryptophane-A derivatives bound to Xe is roughly 87 Å3 and can expand to
~100 Å3 to accommodate a much larger (71 Å3) CDCl3 guest.12 We can assume that
TTEC bound to either Xe or Rn adopts a very similar geometry to the previous 4-Xe
crystal structure (Figure 2.6).12 As evidenced by this structure, Xe underfills the
cryptophane cavity, interacting over tenths of angstroms with the phenyl carbon atoms in
both cyclotriguaiacylene caps. The somewhat larger, more polarizable Rn atom is
expected to exhibit stronger van der Waals interactions with TTEC than Xe, as supported
by the measured enhancement in free energy of binding.
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Figure 2.6. Structure of 4-Xe complex determined from X-ray crystallography.12 van der
Waals radii are shown for Xe (blue sphere) and carbon atoms of one pair of opposing
phenyl groups. Hydrogen atoms have been removed for clarity. Rn is expected to bind to
the same site in TTEC, while occupying 10-15% more of the interior cavity volume.
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Despite the institution of government-sponsored detection and remediation
programs in many countries,29 contemporary assessments show that radon exposure
remains the second leading cause of lung cancer, after smoking, in the United States.30,31
While the environmental health risks posed by radon are well recognized, studies of
radon binding to well-defined synthetic or biological targets have not been performed;
studies have tended to focus on the association of radon progeny, not radon itself.32
Challenges in this work have been to obtain pure 222Rn and make binding measurements
on very small quantities of material. In the current study, pure radon was obtained by
sealing

226

RaCl2 solution inside of polyethylene capsules permeable only to the gaseous

emanation. These capsules, placed in a sealed 10.6-mL water-filled vessel, generated a
useful concentration of 222Rn within roughly one week as a steady state was approached.
This solution provided sufficient

222

Rn for tens of binding measurements. This method

requires the radium-filled capsules to be properly sealed, and all

222

Rn manipulations

must be performed using gas-tight syringes inside of a laboratory fume hood. With these
precautions, this method has broad utility for the study of radon binding to many different
biological samples, biomolecules, or other small-molecule hosts.

The concepts of supramolecular chemistry33,34 can be usefully applied to the study
of radon binding. For example, many organic cavitands should bind radon with
appreciable affinity, based on radon’s considerable polarizability and molecular volume,
which is similar to that of dichloromethane. This study showed that a water-soluble
cryptophane-A derivative binds radon with considerable affinity. Indeed, TTEC may
provide a nearly optimal cavity for radon as its internal volume (~90 Å3, assuming
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modest expansion from the average 4-Xe structure)12 is approximately twice the radon
atomic volume.35 Furthermore, in lieu of three ethylamine groups, tripropargylated 4 can
be reacted with a wide variety of water-solubilizing azido-linkers that may fine-tune the
host-noble gas interaction.12-14

Considering our previous study of the analogous tris(triazole propionic acid)
cryptophane,14 it is striking that a tris-carboxylate to tris-amine substitution at the
cryptophane periphery increased the Xe association constant from 17,000 M-1 to 42,000
M-1 at 293 K. In order to explore the role of electrostatic interactions, we investigated
xenon binding to TTEC at pH 2.5 (Figure 2.7) and 7.5 (Figure 2.3). As shown in Figures
2.8 and 2.9, hyperpolarized 129Xe NMR spectroscopy gave comparable chemical shifts at
298 K for TTEC-129Xe at pH 2.5 (63.8 ppm) and pH 7.5 (64.3 ppm), which is indicative
of very similar Xe binding environments within the cryptophane. Over this pH range the
compound went from a state of predominantly triple protonation at pH 2.5 to mostly
single protonation at pH 7.5 while remaining in solution (Figure 2.10). Slightly higher Xe
binding affinity was observed by ITC at pH 7.5 than pH 2.5 (KA = 42,000 ± 2,000 M-1 vs.
KA = 34,000 ± 1,000 M-1 at 293 K, Figure 2.7). Thus, it appears that electrostatic
interactions, as well as other effects such as cryptophane solvation, are responsible for the
enhanced Xe binding observed in TTEC.
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Figure 2.7. Enthalpogram of 83 µM TTEC (6) in phosphate buffer (20 mM, pH 2.5) at
293 K titrated with saturated aqueous xenon solution (5.05 mM).
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Figure 2.8. Hyperpolarized

129

Xe NMR spectrum showing xenon bound to TTEC (6) in

20 mM phosphate buffer, pH 7.5.
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Figure 2.9. Hyperpolarized

129

Xe NMR spectrum showing xenon bound to TTEC (6) in

20 mM phosphate buffer, pH 2.5.
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Figure 2.10. Titration curve showing the titration of 0.279 micromoles TTEC (6) in 1 mL
of 100 mM NaCl with small aliquots of 50 mM HCl. The acid-base titrations were
performed following the same methodology reported previously.15
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CONCLUSION
The development of high-affinity Xe-binding cages is an area of active
investigation and is critical to the burgeoning field of xenon biosensing.16,36,37 Synthetic
host molecules designed to bind xenon in cells or in vivo must compete against a wide
variety of biological substrates. Xenon is lipophilic and exhibits affinity for cavities in
macromolecular interiors. Xenon's lipophilic behavior has been shown from its partition
with long-chain hydrocarbons38,39 and from its in vitro40 and in vivo41 partition with fatty
tissue. Xenon binding to myoglobin has been well characterized by NMR
spectroscopy42,43 and X-ray crystallography,44 and metmyoglobin-Xe association
constants have been measured to be ~200 M-1 and 10 M-1.44,45 Comparable affinities have
been determined for other naturally occurring sites in hemoglobin,43 lipoxygenase,46 and
lipid transfer protein,47 as well as specially designed hydrophobic cavities in T4
lysozyme,48 ribose-binding protein,49 and other examples.50,51 We showed previously that
xenon binds water-soluble cryptophanes ~1.5-fold less avidly in human plasma than in
aqueous buffer solution.14 Thus, the design of higher affinity xenon-binding molecules
such as TTEC extends the range of possible biological applications. Biologically targeted
cryptophanes are under development as potential

129

Xe MRI contrast agents, as

demonstrated by xenon biosensors for the prototypical biotin-avidin interaction52,53 and
other proteins,54-56 as well as cell studies.57-59 This demonstration of radon binding to
cryptophane raises similar possibilities of molecularly functionalized radon binders for
biological, environmental, and materials applications involving radon delivery,
sequestration, or detection.
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Finally, it is significant that xenon and radon showed similarly tight binding for a
well-defined molecular cavity (TTEC). This suggests that radon, which like xenon is
known to be lipophilic,26,60 also binds with appreciable affinity to many proteins,
surfactants, and small air spaces in the lung and other regions of the body. Radiometric
binding methods developed in the course of this work will enable quantitative
comparisons of radon binding to various biomolecular targets, as a means of assessing
environmental health risk. Such information may ultimately be useful in developing more
effective mitigation strategies for this indoor pollutant.
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EXPERIMENTAL PROCEDURES
Reagents. Organic reagents and solvents were used as purchased from the following
commercial sources:
Sigma-Aldrich:

methanol,

2,6-lutidine;

Acros:

cesium

carbonate,

anhydrous

dimethylsulfoxide (DMSO), anhydrous dimethylformamide (DMF), 70% perchloric acid,
d6-DMSO, CDCl3; Fisher: sodium chloride, potassium phosphate, ethyl acetate,
dichloromethane, hydrochloric acid, sodium hydroxide, sodium sulfate, acetone, hexanes;
Cambridge Isotope Laboratories: deuterium oxide; Airco Industrial Gases: researchgrade xenon gas.

General Methods. All organic reactions were carried out under nitrogen atmosphere.
1

H NMR (500.14 MHz) and 13C NMR (125.77 MHz) spectra were obtained on a Bruker

AMX 500 spectrometer at the University of Pennsylvania NMR facility. Electrospray
ionization mass spectrometry was performed in low-resolution mode on a Micromass LC
Platform and in high-resolution mode on a Micromass Autospec while matrix-assisted
laser desorption/ionization spectrometry (MALDI) was performed on a Bruker Daltonic
Ultraflex III MALDI-TOF-TOF at the Mass Spectrometry Center in the Chemistry
Department at the University of Pennsylvania. Isothermal titration calorimetry (ITC) was
performed using a MicroCal VP-ITC titration microcalorimeter (Northampton, MA). For
ITC measurements in buffer, solutions were prepared with deionized (DI) water obtained
from Mar Cor Premium Grade Mixed Bed Service Deionization (18.2 megohm-cm
resistivity at 25 °C). Column chromatography was performed using 60 Å porosity, 40-75
µm particle size silica gel from Sorbent Technologies. Thin layer chromatography (TLC)
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was performed using silica gel plates with UV light at 254 nm for detection. HPLC
analysis was performed on an Agilent 1100 system equipped with a quaternary pump and
diode array detector using a Varian Microsorb-MV 300-5 C8 column (4.6 × 250 mm, 5
µm). The gradient eluent was composed of two solvents: 0.1% aqueous TFA (solvent A)
and a 0.1% solution of TFA in CH3CN (solvent B). UV-visible spectra were measured
using a diode-array Agilent 89090A spectrophotometer.

Synthesis.

Cyclotriguaiacylene

iodoethoxy)phenyl]methanol

(2)

were

(1),
synthesized

and
using

[3-propargyloxy-4-(2previously

published

protocols.56 The NMR spectra and physical constants also matched the reported literature
data.56
2,7,12-Tris[2-[4-(hydroxymethyl)-2-propargyloxyphenoxy]ethoxy]-3,8,13-trimethoxy10,15-dihydro-2H-tribenzo[a,d,g]cyclononene (3), and tripropargyl cryptophane (4) were
also synthesized using previous protocols.14 The identity and purity of the compounds
were confirmed by matching the NMR spectra and physical constants to reported
literature data.14 2-Azidoethylamine (5) was synthesized in 93% yield, also following
literature precedent.17
Tris(triazole ethylamine) cryptophane (6, TTEC). Tripropargyl cryptophane (4) (10.13
mg, 0.01049 mmol, 1.0 equiv.), 2-azidoethylamine (5) (4.47 mg, 0.0520 mmol, 5.0
equiv.), copper (II) sulfate (0.83 mg, 0.0052 mmol, 0.5 equiv.), 2,6 lutidine (0.11 mg,
0.0010 mmol, 0.1 equiv.), and sodium ascorbate (82.14 mg, 0.4146 mmol, 40 equiv.)
were added to a glass vial with septum cap. Dry DMSO (0.5 mL) was added and the
reaction was magnetically stirred under nitrogen overnight. The product was purified
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using two methods: 1) 0.1 % TFA in DI water was added to the reaction mixture which
led to the precipitation of the product TTEC (6) which was centrifuged and the
supernatant discarded. The white pellet was resuspended in DI water and precipitated by
adding 0.1 % TFA and centrifuged again to separate the supernatant. This was repeated
twice after which the white precipitate was dried under vacuum; 2) The product was also
purified using the HPLC gradient 0.1% TFA in 95% water: 5% acetonitrile to 0.1% TFA
in 20% water: 80% acetonitrile over 75 min. This resulted in 9.73 mg (75% yield) of
TTEC (6) as a white powder. 1H NMR (500 MHz, d6-DMSO): σ 8.20 (s, 3H), 7.09 (s,
3H), 6.88 (s, 3H), 6.82 (s, 3H), 6.80 (s, 3H), 5.12-5.03 (m, 6H), 4.52-4.49 (m, 6H), 4.42
(s, 6H), 4.21-4.09 (m, 18H), 3.51 (s, 9H), 3.38 (d, J = 13.8 Hz, 3H). Heq and α-amino
protons with a total integration of 6H were hidden under residual water peak. 13C NMR
(125 MHz, d6-DMSO) 148.8, 147.8, 146.0, 145.7, 143.3, 133.8, 133.5, 132.6, 131.7,
124.5, 120.7, 119.0, 117.0, 115.0, 68.8, 68.3, 62.8, 56.0, 49.3, 35.0, 29.1; MALDI MS
calcd. for C66H72N12O12 (M + Na+) 1247.539; found 1247.724.

62

Hyperpolarized
commercially

129

Xe NMR Spectroscopy. A home-built version of the previously

available

Nycomed-Amersham

(now

GE)

IGI.Xe.2000

129

Xe

hyperpolarizer was used to generate the hyperpolarized 129Xe gas. A gas mixture of 89%
N2, 10% He, and 1% natural abundance Xe (Spectra Gases) was flowed through the
hyperpolarizer.

129

Xe was hyperpolarized to 10-15% after being cryogenically separated,

accumulated, thawed, and collected in CAV NMR tubes (New Era). After Xe collection,
NMR tubes were shaken vigorously to mix cryptophane solutions with Xe.

All

129

Xe NMR measurements were carried out on a 500 MHz Bruker BioDRX

NMR spectrometer at the University of Pennsylvania NMR Facility. RF pulse frequency
for

129

Xe was 138.12 MHz. Samples were observed using either a 5 mm PABBO NMR

probe or a similar 10 mm probe.

129

Xe NMR spectra were acquired using the Exchange Signal Averaging (ESA)

method.61 Selective pulses (90º flip angle, EBurp1 shaped) were generated at the
Xe@cryptophane resonance frequencies. Each pulse lasted 5 ms, which gave a
designated excitation region ~1 kHz. All spectra were signal averaged by 40 scans. A
delay of 0.15 s was given between scans to allow polarized Xe to exchange in and
depolarized Xe to exchange out of the cryptophane cavity. Sample temperature was
controlled by VT unit on NMR spectrometer to 27 ± 1 ºC.
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HPLC trace for TTEC (6). Column: Microsorb-MV 300-5 C8 250 x 4.6 mm (Varian);
flow rate: 1 mL/min; injected volume: 500 µL; wavelength detection: 280 nm. HPLC
gradient 0.1% TFA in 95% water: 5% acetonitrile to 0.1% TFA in 20% water: 80%
acetonitrile over 75 min. Retention time of TTEC: 25.16 min.

64

1

H NMR of TTEC (6) in d6-DMSO at 298K
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13

C NMR of TTEC (6) in d6-DMSO at 298K
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Xenon Binding Study. Isothermal titration calorimetry (ITC) was performed using a
MicroCal VP-ITC titration microcalorimeter (Northampton, MA).62 TTEC was dissolved
in phosphate buffer (20 mM, pH 7.5) and the concentration (140 µM) was determined by
UV-vis spectroscopy according to the extinction coefficient of TTEC at 280 nm (ε280 =
12,400 M-1cm-1). The preparation of saturated aqueous xenon solution and the
determination of xenon concentration at 293 K were performed following the same
methodology reported previously.14,22 The titrations were carried out at 293 K; 1.8 mL of
the TTEC in 20 mM phosphate buffer was placed in the calorimeter cell, and the
saturated xenon-water solution was loaded into the microsyringe.

The titration was performed by the sequential addition of 15 µL aliquots of xenon
solution (for a total of 19 injections) at 5-min intervals. The heat of reaction per injection
(micro-calories per second) was determined by integration of the peak areas (ORIGIN
7.0, MicroCal software). The values of the binding enthalpy (∆Ho), the stoichiometry of
binding (n), and the association constant (KA) were obtained from fitting the heat evolved
per mole of xenon injected versus the xenon/TTEC molar ratio using the same software.
Three control experiments (see Experimental procedures) were performed with each
phosphate buffer (20 mM) at pH 7.5 or pH 2.5: 1) saturated xenon solution titrated into
buffer; 2) water titrated into TTEC-buffer solution; and 3) water titrated into buffer to
determine the heats of dilution. Processes #1 and #2 were subtracted from, and #3 was
added back to, the corresponding TTEC-xenon binding enthalpogram before curve
fitting.
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Radon Binding Study. Radon was generated from 63 kBq

226

Ra in four polyethylene

capsules submersed in a water-filled 10.6 mL vessel sealed with an aluminum-lined
septum.

Radon was allowed to accumulate in the water for 8 days prior to the

experiment. The emanation fraction (i.e., the ratio of accumulated
generated from

226

222

Rn to the total

Ra decay) for the capsules was about 30%. Stock TTEC solution

concentration (48.3 µM) was determined by UV-vis spectroscopy and radon-in-water
solution concentration (1.002 pM) by LS counting. Glass vials (1.1-mL Chromacol screw
top, Supelco, Bellefonte, PA, USA) sealed with PTFE septa were filled by micropipette
with varying concentrations of cryptophane solution (0.49-5.29 nmol in 120 µL; six
concentrations, each in duplicate, and three null trials), and with radon-in-water solution
(400 µL) from the generator, by 10-mL glass, gas-tight Hamilton syringe. The rest of the
vial was left as airspace. The samples were incubated for 30-40 min at 293 K; each vial
was subjected to two 5-sec vortex mixings, one each at the beginning and end of the
incubation. A 400 µL sample was withdrawn from each vial and injected beneath the
surface of approximately 19 mL LS cocktail that consisted of a commercial scintillation
fluid (Ultima GAB, PerkinElmer, Waltham MA, USA) having a 5% water fraction in a
22-mL Al-foil lined, glass LS vial. LS counting was done using automated equipment
after allowing time for radon to equilibrate with its daughter nuclides. Each sample was
counted for 1 h in two apparatuses with different operational parameters (Beckman
Coulter, Brea, CA, USA; Wallac, PerkinElmer, Waltham, MA, USA).

All liquid

transfers by micropipette and syringe, as well as the precise volumes of the vials, were
quantified gravimetrically.
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The radon determinations were based on well-established LS procedures for the
assay of gravimetrically-determined aliquots of aqueous solutions containing radon in
radioactive equilibrium with its short-lived daughter products.23 Raw LS data were
corrected for background (< 0.3% correction), for the radon content in the airspace above
the cocktail in the LS vials (approx. 0.7 % correction), and for radioactive decay to a
common reference time. Counting was initiated after a minimum of 4 h to ensure that the
radon daughters were in radioactive equilibrium. Each source was measured for 20 min
over a period of 0.2 to 4.9 days on 6 to 10 occasions. The corrected net counting rates
were observed to decay with the radon half-life, indicating that there was no radium
leakage from the capsules. Corrected data were fitted to equation (1) by least-squares
linear regression using MATLAB (Mathworks, Natick, MA, USA) to obtain KA and L.
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CHAPTER 3: TARGETING THE FOLATE RECEPTOR
WITH A FOLATE-CONJUGATED CRYPTOPHANE FOR
CANCER DETECTION
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ABSTRACT

Folate-conjugated cryptophane enables the targeting and delivery of cryptophane
to cells overexpressing folate receptors, which are overexpressed in many human cancers.
The cryptophane biosensor was synthesized in 19 nonlinear steps, which included
functionalization with a folate recognition moiety, solubilizing peptide group and Cy3
dye. Cellular internalization was monitored by confocal laser scanning microscopy
(CLSM). A competitive blocking study confirmed cryptophane endocytosis through a
folate receptor-mediated pathway. Flow cytometry revealed 10-fold higher cellular
internalization in cancer cells overexpressing folate receptors (KB cells) compared to
cells underexpressing folate receptors (HT-1080 cells). The biosensor was determined to
be relatively non-toxic in low folate receptor expressing HT-1080 cells by MTT assay at
the micromolar cryptophane concentrations typically used for hyperpolarized 129Xe NMR
biosensing experiments. In folate overexpressing KB cells, the viability ranged from
100% to 80% from 0 µM to 10 µM and dropped to 50% at 38 µM.

129

Xe NMR studies

were performed and the resulting peak at 65 ppm confirmed xenon binding to the folateconjugated cryptophane. Studies are currently underway to detect the binding of the
folate-conjugated biosensor to monomeric folate binding protein at nanomolar or
picomolar concentrations using Hyper-CEST NMR techniques.
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INTRODUCTION

As mentioned in Chapter 1, magnetic resonance imaging (MRI) is a noninvasive
medical imaging technique used to scan deep tissues with high spatial resolution.
Although it can provide high contrast images of different tissues such as organs and
bones, it is limited by low sensitivity due to the high background-to-signal ratio. In order
to increase signal, especially when imaging vascular tissues or analyzing brain perfusion,
gadolinium- or iron-oxide-based contrast agents are commonly used. However, there are
limitations to these imaging agents. Early and accurate diagnoses of disease states
increasingly rely upon information gleaned from molecular imaging of protein
biomarkers or metabolic processes. There are now many examples using PET and
SPECT imaging agents with readily detected radioactive nuclei.1 By comparison, current
MRI contrast agents have limited ability to detect proteins of low abundance in cells.2,3,4
The goal of making “smart” MRI contrast agents that produce readily measured signal in
response to environmental cues has led to investigation of alternate nuclei, including
hyperpolarized 129Xe, 13C, 38Kr and 3He.5-8

129

Xe is an attractive option for imaging because of its nontoxicity, chemical-shift

sensitivity to its molecular environment and hyperpolarizability. Additionally, watersoluble tris-(triazole ethylamine) and tris-carboxylate derivatives of cryptophane-A have
been developed that bind xenon with large association constants, KA = 17,000-42,000 M-1
in buffer at 293 K. Additionally, one cryptophane was shown to bind Xe in human
plasma with appreciable affinity, KA = 22,000 M-1 at 310K.9 This has led to the synthesis
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of cryptophane-based biosensors that are conjugated to various ligands via a hydroxyl or
propargyl group. As mentioned in Chapter 1, these include a biotin-modified cryptophane
biosensor that can detect streptavidin in vitro,10-13 an enzyme-responsive

129

Xe NMR

biosensor for the detection of matrix metalloproteinase-7 (MMP-7),14 and a series of
benzenesulfonamide-functionalized cryptophane-A derivatives that exhibited the largest
isozyme-specific chemical shift changes (3.0-7.5 ppm), upon binding carbonic
anhydrases I and II.15 Another recent example included the synthesis of a peptide-labeled
129

a

Xe biosensor by Schlundt et al. that produced a 1 ppm downfield shift upon binding to
major

histocompatibility

complex

(MHC)

class

II

protein.16

The delivery of cryptophanes using cell penetrating peptides or by targeting αvβ3 integrin
receptors into cancer and normal cells has also been demonstrated.17,18 The cryptophanes
were minimally cytotoxic and intracellular concentrations of approximately 100 µM were
achieved, which should be sufficient for in vivo hyperpolarized 129Xe MRI studies.17,18

In cells, there are three types of transporters that are responsible for the uptake of
folate. These include RFC (reduced folate carrier),19 proton-coupled high affinity folate
transporter,20 and folate receptor (FR, also known as high affinity folate binding
protein).21 Folate receptors are cell surface glycosylphosphatidylinositol (GPI)-linked
membrane glycoproteins with molecular weights ranging from 38,000 to 45,000 Da.22 It
has a high binding affinity (KD ≈ 0.1-1 nM with a 1:1 stoichiometry) for folic acid and 5methyltetrahydrofolate.22 FR is mainly located on the luminal surface of polarized
epithelial cells. In humans, FR has 4 different types of isoforms: α, β, γ, and δ, where
isoforms α and β are membrane bound.21 Among them, FRα is overexpressed in non-
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mucinous adenocarcinomas of the ovary, cervix, uterus, ependymal brain tumors,whereas
normal cell lines have very low FR expression.23-26 FR expression in normal tissues
mostly is found in polarized epithelial cells in the proximal kidney tubules, choroid
plexus, etc.25,27-31 FRα is overexpressed in 90% of ovarian carcinomas and higher levels
of expression are generally associated with poorly differentiated and aggressive
tumors.31,32 It is believed that FRα is overexpressed because the fast growth rate of cancer
cells requires more folic acid.21 Folic acid is an essential component of the one-carbon
transfer reactions which are crucial for one-carbon, nucleic acid, and amino acid
metabolism, as well as the synthesis and proliferation of cells.33 For instance, in ovarian
cancer cells it was possible to limit cancer cell growth by using a FA-antibody to
decrease FRα expression.34

Although FRα is expressed in normal tissues, their distribution on the luminal
surface of epithelial cells ensures that they are not directly accessible through the blood
stream.21 Therefore, it is expected that for in vivo studies, folate-conjugated agents will be
selectively targeted to tumors overexpressing FRα. Previous studies have shown that FRα
can transport folic acid as well as folic acid conjugates (e.g., imaging agents, proteins,
nanoparticles) via receptor-mediated endocytosis (Figure 3.1).23 Therefore, FRα is a
potential cancer biomarker that would indicate the presence of cancerous abnormalities if
detected by the folate-conjugated

129

Xe biosensor. Additionally, folate remains

essentially unaltered after endocytosis and is stable for several hours after the uptake by
cancer cells.35 All of these characteristics make FRα an attractive marker for the

129

Xe

biosensor to detect.
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Figure 1. Structure of folic acid.
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It has been known for nearly a decade that simple covalent attachment of folic acid to virtually any macromolecule produces a conjugate that can be internalized into
FR-bearing cells in an identical fashion to that of free folic
acid17. Numerous publications have emerged to elucidate
the mechanism and to further define the advantages as
well as the limitations of this technology. To date, folate
conjugates of radiopharmaceutical agents18–23, MRI contrast agents24, low molecular weight chemotherapeutic
agents25, antisense oligonucleotides and ribozymes26–30,
84
proteins and protein toxins17,31–35, immunotherapeutic
agents36–39, liposomes with entrapped drugs40–44 and plasmids45–51 have all been successfully delivered to FR-express-
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In this study, a folate-conjugated water-soluble cryptophane biosensor (Figure
3.2) was synthesized, which was envisioned to target cancer cells that are known to
overexpress FRα. The biosensor was composed of four functional components. The first
was the monopropargylated cryptophane-A derivative, which is known to bind xenon in
organic and aqueous solvents.14 The second part was the solubilizing moiety, which
consists of a polycationic peptide (RKR) where the positive charges are deliberately
broken up by a polyethyleneglycol unit (PEG). This is because polycation sequences of
five or greater peptide units are known to induce non-specific uptake of peptide
conjugates into cells.37 The third component consisted of the Cy3 fluorescent dye, which
is conjugated through a maleimide linkage to the cysteine residue on the peptide
sequence. The dye was included to assist in the visualization of the biosensor in both FR+
and FR- cells by confocal laser scanning microscopy and flow cytometry. Lastly, a folate
recognition moiety that has a high affinity for FRα was conjugated via an orthogonally
protected lysine on the peptide sequence. The last step in the synthesis involved the
conjugation of the N-terminal azide of the peptide-folate conjugate to monopropargylated
cryptophane by a Cu(I)-catalyzed [3+2] Huisgen cycloaddition.38-40 Selective cell uptake
and cytotoxicity studies were performed using confocal laser scanning microscopy, flow
cytometry and MTT assays for KB and HT-1080 cancer cells.
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Figure 3.2. Structure of the FRα-targeting

129

Xe NMR biosensor, with a xenon-binding

cryptophane, solubilizing peptide, FRα targeting moiety (blue) and fluorescent Cy3 dye
for in vitro studies (red).
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RESULTS AND DISCUSSION
Synthesis and characterization of folate-cryptophane conjugate

Synthesis of α-[2-(Trimethylsilyl)ethoxy]-2-N-[2-(trimethylsilyl)ethoxycarbonyl]folic acid (“folate recognition moiety”). The conjugation of folic acid
to the peptide sequence with DCC would lead to the synthesis of a mixture of α-folate
and γ-folate conjugates. Because only the γ-conjugate is recognized by the FRα receptor,
a selectively protected folic acid derivative 7 was synthesized in 5 nonlinear steps in 13%
overall yield (Scheme 3.1).41 The folate recognition moiety was prepared from two
intermediates: the 2-N-teoc-pteroic acid derivative, where the teoc group is 2(trimethylsilyl)ethoxycarbonyl, and the α-carboxyl-protected glutamic acid.41 Folic acid
(1) undergoes enzymatic hydrolysis with carboxypeptidase-G to give pteroic acid (2).
Carbonyldiimidazole (CDI) and 2-trimethylsilylethanol in dry dimethyl sulfoxide
(DMSO) were added to the crude pteroic acid to produce the protected pteroic acid, 1-(2N-teoc-pteroyl)imidazole (3) in 62% yield. In order to synthesize the second
intermediate, the α-carboxylate group in N-Boc-L-Glu (OBn)-OH (4) was protected by
treating it with CDI and 2-trimethylsilylethanol while the γ-carboxylate group was
selectively deprotected using Pd-‐C to give 5 in 88% yield. The N-Boc group was also
deprotected using TsOH to give α-(2-TMS-ethyl) glutamate 6 in 51% yield. Finally, 3
was treated with 1.5 equiv. of 6 and N-methyl-1,5,9-triazabicyclo[4.4.0]-decene (MTBD)
in dry DMSO to give the folate recognition moiety in 41% yield.
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The monopropargylated derivative of cryptophane-A was also synthesized in 12
nonlinear steps in 3% overall yield (Scheme 3.2, 3.3 and 3.4).14
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Scheme 3.2. 3-step synthesis of a cyclotriguaiacylene (CTG) unit. Figure adapted from
Wei et al.14
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The azidopeptide 22 was synthesized by standard solid-phase synthesis using
Fmoc-substituted reagents.42 3-Azido propionic acid was prepared according to literature
procedures and incorporated as the N-terminal residue. 43 The peptide 22 was synthesized
in 85% yield and consisted of three polyethylene glycol units and lysine-arginine units to
help solubilize the biosensor in water. The cysteine in the peptide chain was included to
fluorescently label the biosensor for in vitro studies. The azidopeptide was orthogonally
deprotected using 4% hydrazine in water and readily coupled to the γ-folate conjugate 7
using coupling agents in dry DMF to yield 23 in 75% yield. In order to monitor the
reaction, a portion of the reaction mixture was cleaved from the resin and purified by
reverse-phase HPLC (see Experimental procedures). Once the formation of the product
was confirmed, 23 (on solid support) was coupled to monopropargylated cryptophane-A
to give 24 by Cu(I)-catalyzed [3+2] cycloaddition. Although the yield for 24 was initially
low (~20% yield), it was significantly improved to approximately 80% by using a large
excess of sodium ascorbate (40 equiv.) to ensure that copper remained reduced as Cu(I)
to catalyze the reaction. The product was purified by reverse-phase HPLC (see
Experimental procedures) and was determined to be readily soluble in water. To
fluorescently label the conjugate 24, the cysteine was deprotected using TCEP and
coupled with the maleimide functionalized Cy3 dye (excitation 550 nm and emission 575
nm). Cy3 labeling efficiencies were determined from the ratio of dye absorbance at 550
nm to the cryptophane absorbance at 280 nm. 25 was purified by reverse-phase HPLC
(see Experimental procedures) and the yields at 20-30% were lower than expected. The
removal of excess TCEP using a gel filtration column did not assist in increasing the
yields.
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Figure 3.3. Cytotoxicity assays for folate-conjugated cryptophane biosensor in KB
(blue), and HT-1080 cells (red). %Viability was determined via MTT assay after 24 h
incubation with increasing concentrations of 24, as compared to untreated cells.

95

In order to perform cell cytoxicity and uptake studies, two cell lines were
selected. KB cells (a cell line derived from human carcinoma of the nasopharynx) were
selected because they are known to highly overexpress FRα while HT-1080 cells (a
fibrosarcoma cell line) are known to underexpress FRα relative to KB cells. The
cytotoxicity of 24 was evaluated by adding increasing concentrations (0 to 100 µM) of
the folate-cryptophane conjugate 24 to KB (FR+) and HT-1080 (FR-) cells, as shown in
Figure 3.3. In KB cells, the viability (scaled to 100% at 0 µM) decreased from 80% at 10
µM to 50% at 38 µM. Maximum toxicity in KB cells (23% viability) was found when the
cells were incubated with the highest concentration of 24 (100 µM). Cell viabilities
determined when 0-10 µM of the biosensor was added to KB cells were comparable to
those seen with fluorescent contrast agents such as folate-substituted poly(pphenyleneethynylene).44 At concentrations ~2 µM, 25 exhibited sufficient fluorescence
intensity to be detected inside the intracellular domain both via confocal miscroscopy and
flow cytometry and was also minimally cytotoxic. The viability of HT-1080 cells ranged
from 100% at 0 µM to 82% at 100 µM of 24. The higher viability of HT-1080 cells
indicates minimal toxicity in human cell lines that do not overexpress FRα. In general, 24
was more cytotoxic to cancer cells that are FR+ than those that are FR-. This is likely due
to the higher levels of FRα that are expressed on KB cells versus HT-1080 cells, which in
turn causes increased intracellular accumulation of biosensor 24. Similar trends were seen
in a previous study where a cyclic RGD peptide-conjugated cryptophane was determined
to be more toxic in cell lines overexpressing the targeted αvβ3 integrin receptors (60%
toxicity in ASPC-1 cells versus 30% toxicity in HFL-1 cells) after 24 h incubation at 100
µM concentration.
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A
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F

Figure 3.4. Uptake of 4 µM Cy3-labeled 25 targeting FRα in KB (a), HeLa (b), and HT1080 (c) cells after 4 h incubation at 37 °C in folic acid depleted media; (d, e, f) Uptake
of 25 was successfully blocked in the KB, HeLa and HT-1080 cell lines, respectively,
when they were incubated in media containing folic acid.
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In order to determine whether 25 could be selectively delivered to FR+ cells,
confocal laser scanning microscopy (CLSM) was performed as shown in Figure 3.4.
After 4 h incubation with Cy3-labeled 25, fluorescence was seen evenly distributed in the
perinuclear region of KB cells as expected for receptor-mediated endocytosis (Figure
3.4a). This is desirable as nuclear internalization of imaging agents can cause potential
mutagenic effects on healthy cells. Cell uptake of Cy3-labeled 25 in HeLa cells was also
confirmed by CLSM after 4 h incubation (Figure 3.4b). The fluorescence intensity was
lower in HeLa cells which was expected due to the highest overexpression of FRα in KB
cells, followed by HeLa and HT-1080 cells. Uptake of 25 was even lower in HT-1080
(FR-) cells, thereby indicating that biosensor 25 was able to discriminate between FR+
and FR- cells (Figure 3.4c). To analyze whether the uptake of 25 was facilitated by folate
receptor-mediated endocytosis, 25 was co-incubated with folic acid rich medium in both
KB, HeLa, and HT-1080 cells. Because folic acid is known to have a very high affinity
for FRα, it was expected to outcompete 25, thereby blocking uptake. The reduction in
fluorescence in Figures 4d-4f indicates that the folic acid did in fact inhibit uptake of 25
and 25 was specifically recognized by the FR receptor. Indeed, the folate recognition
moiety subunit was critical for cellular uptake of the biosensor.
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Figure 3.5. Monitoring the accumulation of 4 µM Cy3-labeled 25 in (a) HT-1080 (FR-,
blue) and (b) KB (FR+, red) cells using flow cytometry. Inhibition of uptake with free
folic acid in the medium was indicated in (a) HT-1080 cells (black) and (b) KB cells
(black).
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In an effort to quantify the selective cellular internalization of 25 in KB and HT1080 cells, flow cytometry was performed. After 4 h incubation in both KB and HT-1080
cells, there was a dramatic increase in cell-associated fluorescence. When biosensor 25
was co-incubated with excess folic acid, the increase in median fluorescence intensity
was much lower than when folic acid was absent. This was in agreement with the results
from the CLSM studies, where uptake was significantly lowered when excess folic acid
was present. In the absence of folic acid, the median cell-associated fluorescence
intensity was approximately 45-fold higher in KB cells and 2.5-fold higher in HT-1080
cells. Therefore, it was determined that the median fluorescence intensity in KB cells was
approximately 10-fold higher than in HT-1080 cells. This was expected because KB cells
are known to overexpress FRα compared to HT-1080 cells,45,46_ENREF_42 and shows
that biosensor 25 was able to selectively target cancer cells overexpressing the intended
receptors.
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Figure 3.6. Hyperpolarized

129

Xe NMR spectrum of 60 µM 24 in acetate buffer at pH

5.0 (40 scans; S/N ≈30:1 at 50 Hz line broadening)
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Hyperpolarized 129Xe NMR spectrum of 24 was performed at 60 µM in both PBS
buffer at pH 7.5 and acetate buffer at pH 5.0 using a 10 mm probe and a BURP pulse.
Figure 3.6 shows 129Xe NMR chemical shifts of 64.91 and 66.11 ppm due to the presence
of the two diastereomers for biosensor 24. This was due to the chirality of the three
components, folate, peptide and cryptophane-A (LLL and LLR). Cryptophane-A is a
chiral molecule and the racemic mixture of enantiomers encapsulating xenon has been
reported to give rise to a single NMR resonance.47 However, upon conjugation of chiral
moieties to this racemic mixture of cryptophanes, diastereomers are formed. Previous
examples of xenon biosensors that contain multiple diastereometers include the biotinconjugated cryptophane developed by Spence et al.10 The biosensor consisted of four
diastereomers due to the chiral cryptophane-A, L-amino acids, and maleimide center
formed when the biotin was conjugated to the rest of the biosensor (RLR, RLL, LLR,
LLL).10 This resulted in 4 distinct peaks in the

129

Xe NMR spectrum. Similarly, the

enzyme-responsive MMP-7 biosensor developed in our lab also indicated the presence of
two diastereomers that were separated by 0.6 ppm. This was due to the chirality of the
two components, peptide and cryptophane-A (RL and LL).14,47,48 Carbonic anhydrase
targeting cryptophane biosensors also developed in our lab are hypothesized to form
diastereomers when the two enantiomers that make up the biosensor interact with the
chiral protein surface.15,49 Since for multiplexing purposes it would be preferable to only
have single NMR resonances for biosensors targeting different biomarkers, the synthesis
of enantiomerically pure cryptophanes is currently underway in our lab and will be
discussed in further detail in Chapter 5.
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129

Xe NMR experiments were also performed with 24 and folate binding protein

(FBP) to determine the change in the chemical shift upon binding to the protein. FBP is
an expensive membrane-bound protein and is known to aggregate at low micromolar
concentrations.50 Specifically, the MW of the monomeric protein is 29,000 Da and
increases to approximately 300,000 Da during aggregation.50 Although it would have
been desirable to perform the

129

Xe NMR experiments at nanomolar concentrations, due

to the sensitivity limitations of our system, micromolar concentrations had to be used. To
minimize aggregation, all the NMR experiments were carried out at pH 5.0 in acetate
buffer as it is known that the protein experiences lower aggregation in this buffer than at
pH 7.0.50,51 In the first trial, 30 µM FBP was mixed with 60 µM of the biosensor.
Although the spectrum indicated the presence of the cryptophane peak, there was no new
peak indicating that the biosensor was bound to FBP. In a second trial, the sample was
allowed to equilibrate for 30 min and vortexed to ensure good mixing. The results were
similar to those of trial 1 where no distinct bound signal was observed. In a third trial, a
lower concentration of biosensor (30 µM) was mixed in an NMR tube with 30 µM FBP
but again no new bound peak was observed, only dilution of the free cryptophane peak.
Additionally, 10% glycerol was added to the buffer for all

129

Xe NMR experiments to

prevent foaming and stabilize the protein. The lack of a cryptophane bound peak could be
due to several reasons: a) protein aggregation that prevents folate binding,50 b) when
cryptophane associates with FBP, Xe is unable to gain access, and c) the cryptophane
itself may preclude the folate recognition moiety from binding to the protein. All these
reasons would lead to a loss in the 129Xe bound signal. Our lab’s improving capabilities in
hyperpolarized

129

Xe NMR spectroscopy will soon make it possible to perform these
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measurements in live cells, which will help to troubleshoot the potential problems
outlined above.
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CONCLUSION

In summary, a novel water-soluble folate-conjugated cryptophane biosensor was
synthesized and characterized. The folate moiety had been selectively protected to ensure
that only the α-carboxylate group was available to bind to FRα. Confocal imaging with
KB (FR+) and HT-1080 (FR-) cells indicated the selective uptake of the biosensor via
folate receptor-mediated endocytosis into cells overexpressing FRα. Flow cytometry
analysis indicated that uptake was 45-fold higher in KB cells and 2.5-fold higher in HT1080 cells than when competing excess folate was in solution. Also, the median
fluorescence intensity was approximately 10-fold higher in KB cells than in HT-1080
cells, which motivates the use of this folate-conjugated cryptophane for in vivo
biosensing in cells overexpressing FRα. Cytotoxicity assays indicated that in the relevant
ranges required for confocal and flow cytometry analysis (0-10 µM), the viability was
greater than 80% in both cells lines.

129

Xe NMR spectroscopy as well cellular

spectroscopy studies that can be performed using low concentration of proteins and cells
are currently underway and will be discussed in Chapter 5.
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EXPERIMENTAL PROCEDURES
Reagents
Sigma-Aldrich: Dimethyl sulfoxide (DMSO), dimethylformamide (DMF), folate binding
protein (FBP), folic acid, methanol, triisopropylsilane (TIS), 2,6-lutidine, piperidine, 3(4,5- dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT);
Fisher: sodium chloride, copper(II) sulfate, trifluoroacetic acid (TFA), diethyl ether
(Et2O), glutathione
Alfa Aesar: Cesium carbonate, L-glutathione
Novabiochem:

2-(1H-benzotriazole-1-yl)

1,1,3,3-tetramethyluronium

hexafluorophosphate (HBTU), N-Hydroxybenzotriazole (HOBt), N-methylmorpholine
(0.4 M), Fmoc-15-amino-4,7,10,13 tetraoxapentadecanoic acid ((PEG)3), Rink amide
resin, Fmoc-protected amino acids including Fmoc-L-Lys(ivDde)-OH, Fmoc-LLys(Boc)-OH, Fmoc-L-Arg(Pbf)-OH, Fmoc-Cys(tButhio)-OH, N-methylmorpholine (0.4
M)
GE Healthcare: Cy3 monoreactive dye pack
Calbiochem: Tris(2-carboxyethyl)phosphine hydrochloride (TCEP-HCl)
Invitrogen: RPMI-1640 medium, folate-depleted RPMI-1640 medium, Dulbecco’s
phosphate buffered saline (DPBS)

For biological assays, all solutions were prepared using deionized water purified by Mar
Cor Premium grade Mixed Bed Service Deionization.
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General Methods. All organic reactions were carried out under nitrogen atmosphere.
1

H NMR (500.14 MHz) and 13C NMR (125.77 MHz) spectra were obtained on a Bruker

AMX 500 spectrometer at the University of Pennsylvania NMR facility. Electrospray
ionization (ESI) mass spectrometry was performed in low-resolution mode on a
Micromass LC Platform and in high resolution mode on a Micromass Autospec while
matrix-assisted laser desorption/ionization spectrometry (MALDI) was performed on a
Bruker Daltonic Ultraflex III MALDI-TOF-TOF at the Mass Spectrometry Center in the
Chemistry Department at the University of Pennsylvania. Column chromatography was
performed using 60 Å porosity, 40-75 µm particle size silica gel from Sorbent
Technologies. Thin layer chromatography (TLC) was performed using silica gel plates
with UV light at 254 nm for detection. HPLC analysis was performed on an Agilent 1100
system equipped with a quaternary pump and diode array detector using a Varian
Microsorb-MV 300-5 C8 column (4.6 × 250 mm, 5 µm). The gradient eluent was
composed of two solvents: 0.1% aqueous TFA (solvent A) and a 0.1% solution of TFA in
CH3CN (solvent B). UV-visible spectra were measured using a diode-array Agilent
89090A spectrophotometer.

Synthesis of 22. Peptide 22 (Scheme 3.5) was prepared by solid-phase synthesis using
standard Fmoc amino acid protection chemistry on Rink Amide resin (0.1 mmol scale).
Couplings of Fmoc-protected amino acids to the resin were carried out with HBTU and
N-methylmorpholine to generate the activated ester. The resin was swelled in DMF (10
min) prior to synthesis. Amino acids were then added sequentially until 3-azidopropionic
acid was attached at the N-terminus as the final step. All residues were coupled onto resin
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by the following procedure: removal of Fmoc group (20% piperidine solution in DMF, 2
× 5 min), wash (DMF, 6 × 30 s), activation (amino acid/HBTU/N-methylmorpholine, 1 ×
30 s) coupling (amino acid/HBTU/N-methylmorpholine, 1 × 60 min), rinse (DMF, 3 × 30
s). The peptide was swelled in DMF for 10 min and the orthogonal lysine was
deprotected by washing the resin five times with 4% hydrazine in DMF. The resin was
dried and the peptide was cleaved using a mixture of TFA, TIS, and water (90/5/5) at rt
for 4 h. The reaction mixture was filtered using a peptide vessel, concentrated and the
peptide was precipitated by the addition of ether. The cleavage cocktail removed side
chain protecting groups from all amino acids except for the t-butylthiol-protected
cysteine. Semi-preparative HPLC purification of 22 was accomplished using the
following gradient: time 0, A/B = 95/5; 0-45 min, linear increase to A/B = 50/50; 45-47
min, linear increase to A/B = 20/80; 47-56 min, linear change to A/B = 20/80; 56-57 min,
linear increase to A/B =95/5; 57-72 min, linear change to A/B = 95/5. MALDI MS
calculated for peptide 22, C72H141N31O16S2 (M + H+) 1761.06; found 1760.91.

Synthesis of 7. α-[2-(Trimethylsilyl)ethoxy]-2-N-[2-(trimethylsilyl)-ethoxycarbonyl]folic
acid (7) was prepared according to literature procedure41 and matched the reported
physical constants and NMR spectra.

Synthesis of 21. Monopropargyl cryptophane was prepared according to literature
procedure14 and matched the reported physical constants and NMR spectra.
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Synthesis of 23. Peptide 22 on the Sieber Amide resin (30 mg, maximum 0.0201 mmol
azidopeptide, 1 equiv.) was allowed to swell in DMF (500 µL) in a 10 mL peptide vessel
for 10 min. The solution was filtered and 1 mL of 4% hydrazine in DMF was added to
deprotect the ivDde group on the orthogonally protected lysine. This was repeated 5
times and the absorption of the filtrate at 290 nm was monitored using a UV-vis spectrum
to ensure that the deprotection had taken place. The resin was then was dried under
vacuum. 22 was then added to a mixture of 7 (0.0402 mmol, 2 equiv.), HBTU (0.0603
mmol, 3 equiv.), HOBt (0.0905 mmol, 4.5 equiv.), DIEA (0.1206 mmol, 6 equiv.) in dry
DMF. The reaction was stirred overnight at room temperature under nitrogen. Once the
reaction was complete, the resin was carefully transferred to a fritted reaction vessel and
washed sequentially with DMF, CH2Cl2, MeOH, 1:1 MeOH/CH2Cl2 and MeOH before
drying under vacuum. The peptide coupled to folate 23 was cleaved from the resin using
a mixture of TFA, TIS, and water (90/5/5) at rt for 4 h. The reaction mixture was filtered
using a peptide vessel, concentrated and the peptide was precipitated by the addition of
ether. The cleavage cocktail removed side chain protecting groups from all amino acids
except for the t-butylthiol-protected cysteine. Semi-preparative HPLC purification of 23
was accomplished using the following gradient: time 0, A/B = 95/5; 0-45 min, linear
increase to A/B = 50/50; 45-47 min, linear increase to A/B = 20/80; 47-56 min, linear
change to A/B = 20/80; 56-57 min, linear increase to A/B =95/5; 57-72 min, linear
change to A/B = 95/5. MALDI MS calculated for peptide-folate conjugate 23,
C91H158N38O21S2 (M + H+) 2184.19; found 2184.05.
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Synthesis of 24. Monopropargylated cryptophane (20 mg, 0.02186 mmol, 2 equiv.) in
900 µL dry DMSO was added to 23 (18.2 mg on solid support, maximum 0.01093 mmol
azidopeptide, 1 equiv.) and allowed to stir for 10 min. 2,6-lutidine (0.0219 mmol, 1
equiv.) was added and the reaction mixture was degassed. Sodium ascorbate (0.4372
mmol, 40 equiv.) was added dropwise, the mixture was degassed and finally an aqueous
solution of copper(II) sulfate (0.0054 mmol, 0.5 equiv.) was added. The suspension was
degassed with N2 and stirred at rt for 24 h. The resin was then carefully transferred to a
fritted reaction vessel and washed sequentially with CH2Cl2, MeOH, water, and 1:1
MeOH/CH2Cl2 before drying under vacuum. The [3+ 2] cycloaddition reaction between
the azide-terminated folate-peptide 23 and monopropargylated cryptophane generated the
folate-peptide-cryptophane conjugate 24 which was cleaved from the resin using a
mixture of TFA, TIS, and water (90/5/5) at rt for 4 h. The reaction mixture was filtered
using a peptide vessel, concentrated, and the peptide was precipitated by the addition of
ether. The cleavage cocktail removed side chain protecting groups from all amino acids
except for the t-butylthiol-protected cysteine. Semi-preparative HPLC purification of 24
was accomplished using the following gradient: time 0, A/B = 95/5; 0-65 min, linear
increase to A/B = 30/70; 65-68 min, linear increase to A/B = 20/80; 68-70 min, linear
increase to A/B = 5/95. MALDI MS calculated for 24, C147H211N38O32S2 (M + H+)
3102.61; found 3103.08.

Synthesis of 25. Cys-protected folate-peptide-cryptophane conjugate 24 was dissolved
in PBS buffer (100 mM, pH 7.1) at a concentration of 60 µM. The GE protocol was
followed to deprotect the t-butylthiol group and label the cysteine with the Cy3maleimide construct. TCEP (0.0006 mmol, 10 equiv.) was added to a 1 mL PBS solution
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containing 24 and degassed. The solution was stirred for 40 min to which was added Cy3
dye dissolved in 50 µL dry DMSO. The reaction was degassed and stirred under nitrogen
at rt for 16 h. The reaction mixture was purified by HPLC using the following gradient:
For Cy3-labeled 25: time 0, A/B = 95/5; 0-65 min, linear increase to A/B = 30/70; 65-68
min, linear change to A/B = 20/80; 68-70 min, A/B = 5/95. MALDI MS calculated for
C180H253N42O42S3 (Cy3-I) (M+ H+) 3771.81; found 3771.59. Extinction coefficients used
to determine solution concentrations of Cy3-labeled 25 was ε280 38,000 M-1 cm-1 and ε552
150,000 M-1 cm-1 in water.

Cell Culture. KB, HeLa and HT-1080 cells were obtained from Dr. Jerry Glickson
(University of Pennsylvania Medical School, Philadelphia, PA). All cells were grown in
25 cm2 tissue culture flasks in RPMI-1640 with 25 mM HEPES supplemented with
2 mM L-glutamine, 15% fetal calf serum, 100 units of penicillin, and 100 units of
streptomycin. Cells were subcultured on a weekly basis.

Cell Viability (MTT) Assay. In 96 well plates, 25,000 KB and HT-1080 cells were
plated per well and allowed to grow overnight. A stock solution of nonfluorescently
labeled folate-peptide-cryptophane conjugate 24 was added to wells in triplicate at final
concentrations of 0, 2, 10, 25, 50, 75, and 100 µM and incubated for 24 h in the dark. The
medium was aspirated and the cells were washed thrice with DPBS before being treated
with 20 µL of MTT for 3 h. The medium was removed and DMSO was added to
solubilize the resulting crystals. A plate reader was used to record the absorbance at 540
nm. Absorbance readings were subtracted from the value of wells containing untreated
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cells, and the reduction in cell growth was calculated as a percentage of control
absorbance in the absence of any treatment. Data show the mean of at least three
independent experiments ± SD.

Cell Uptake Studies. KB, HeLa and HT-1080 cells were grown to confluence onLabTek
8-well microscope slides with glass coverslip bottoms at a density of 50,000 cells per
plate. The cells were grown in folate-depleted media or 24 h prior to incubation with 4
µM solution of Cy3-labeled 25 for 4 h at 37 oC. For blocking studies, cells were grown in
media containing folic acid for 24 h prior to incubation with 25 under the same
conditions mentioned above. The medium was removed and the cells were washed three
times with DPBS. Cells were visualized using an Olympus FV1000 confocal laser
scanning microscope with 543 nm (HeNe) laser excitation and Cy3 emission filter under
40× magnification (Olympus UApo/340 40×, 1.15 W).

Flow Cytometry Experiments. KB and HT-1080 cells were seeded in T25 flasks each
containing 106 cells and grown for 1 day in folate-depleted RPMI-1640 medium. The
cells were incubated for 4 h with 4 µM 25 (1.3 mL/flask). For blocking studies, 4 µM 25
was added in the presence of medium containing folic acid. The medium was aspirated
and cells washed 3 times with 2 mL of PBS. The cells were detached using trypsinEDTA and centrifuged. The supernatant was aspirated and resuspended in 650 µL 10%
FBS in Dulbecco’s PBS and immediately analyzed on a BD LSRII machine at the Flow
Cytometry Laboratory, Abramson Cancer Center, at the University of Pennsylvania.

112

1

H NMR of the folate recognition moiety (7) in d6-DMSO at 298K
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13

C NMR of the folate recognition moiety (7) in d6-DMSO at 298K
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HPLC purification trace for compound 22 (peptide)
mVolts
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Semi-preparative HPLC purification of 22 was accomplished using the following
gradient at 280 nm: time 0, A/B = 95/5; 0-45 min, linear increase to A/B = 50/50; 45-47
min, linear increase to A/B = 20/80; 47-56 min, linear change to A/B = 20/80; 56-57 min,
linear increase to A/B =95/5; 57-72 min, linear change to A/B = 95/5. Retention time:
27.96 min.
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MALDI spectrum of purified compound 22 (peptide)
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HPLC purification trace for compound 23 (peptide-folate conjugate)

mVolts
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Semi-preparative HPLC purification of 23 was accomplished using the following
gradient at 280 nm: time 0, A/B = 95/5; 0-45 min, linear increase to A/B = 50/50; 45-47
min, linear increase to A/B = 20/80; 47-56 min, linear change to A/B = 20/80; 56-57 min,
linear increase to A/B =95/5; 57-72 min, linear change to A/B = 95/5. Retention time:
26.31 min.
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HPLC trace for compound 24 (peptide-folate-cryptophane conjugate)

mVolts
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Semi-preparative HPLC purification of 24 was accomplished using the following
gradient at 280 nm: time 0, A/B = 95/5; 0-65 min, linear increase to A/B = 30/70; 65-68
min, linear increase to A/B = 20/80; 68-70 min, linear increase to A/B = 5/95. Retention
time: 18.73 min.
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HPLC trace for compound 25 (peptide-folate-cryptophane conjugate)
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Semi-preparative HPLC purification of 25 was accomplished using the following
gradient at 280 and 550 nm: time 0, A/B = 95/5; 0-65 min, linear increase to A/B =
30/70; 65-68 min, linear change to A/B = 20/80; 68-70 min, A/B = 5/95. Retention time:
39.67 min.
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ABSTRACT
A gyroscope-inspired tribenzylamine hemicryptophane provides a vehicle for
exploring the structure and properties of multiple p-phenylene rotators within one
molecule. The hemicryptophane was synthesized in three steps in good overall yield
using mild conditions. Three rotator-forming linkers were cyclized to form a rigid
cyclotriveratrylene (CTV) stator framework, which was then closed with an amine. The
gyroscope-like molecule was characterized by 1H NMR and 13C NMR spectroscopy, and
the structure was solved by X-ray crystallography. The rigidity of the two-component
CTV-trismethylamine stator was investigated by 1H variable-temperature (VT) NMR
experiments and molecular dynamics simulations. These techniques identified gyration of
the three p-phenylene rotators on the millisecond time scale at -93 °C, with more dynamic
but still hindered motion at room temperature (27 °C). The activation energy for the pphenylene rotation was determined to be ∼10 kcal mol-1. Due to the propeller
arrangement of the p-phenylenes, their rotation is hindered but not strongly correlated.
The compact size, simple synthetic route, and molecular motions of this gyroscopeinspired tribenzylamine hemicryptophane make it an attractive starting point for
controlling the direction and coupling of rotators within molecular systems.

130

INTRODUCTION
Synthetic chemical systems provide means to explore complex phenomena in
biological machines1-8 and also to create novel molecular mechanical components.9
Designs based on macroscopic devices include brakes, gears, propellers, rachets,
turnstiles, rotors, scissors, and most recently gyroscopes (Figure 4.1).3,10-14 These
molecular systems have been extensively studied in solution, in solid phases, on surfaces
and in polymers.15 One challenge in designing these systems is the required restriction of
some molecular degrees of freedom, while allowing specific motions of targeted
molecular components.9 Synthesis of such molecules can also be challenging. Criteria
for the construction of molecular gyroscopes have been identified and generally applied:
rotary elements (rotators) are attached to a static framework (stator); steric contacts,
internal rotation barriers, and interaction with solvent should be minimized to allow lowfriction, low-barrier rotary motion; rotating groups are isolated and/or well-separated
from each other.
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Figure 4.1. Examples of molecular components designed to mimic macroscopic devices:
a) Molecular “turnstile” developed by Moore and Bedard et al., b) Metal-centered threespoke molecular gyroscopes developed by Gladysz et al., and c) Solid-state crystals
developed by Garcia-Garibay et al. Figures were adapted from Skopek and Sykes et
al.13,14
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One challenge in designing these systems is the required restriction of some
molecular degrees of freedom, while allowing specific motions of targeted molecular
components.9 Synthesis of such molecules can also be challenging. Criteria for the
construction of molecular gyroscopes have been identified and generally applied: rotary
elements (rotators) are attached to a static framework (stator); steric contacts, internal
rotation barriers, and interaction with solvent should be minimized to allow low-friction,
low-barrier rotary motion; rotating groups are isolated and/or well-separated from each
other.

To expand upon these criteria, we designed a gyroscope-inspired framework with
cyclotriveratrylene (CTV) and trismethylamine as the 2-component stator, bridged by
three p-phenylene rotators (Scheme 4.1). This creates a new application for CTV, which
has been used previously for the synthesis of cryptophanes in host-guest chemistry (with
biosensing and chiroptical properties),16-31 supramolecular assemblies, gels and organic
microporous polymers:32 CTV provides a rigid hemicryptophane framework for the
synthesis of a novel gyroscope-inspired molecule. Our design incorporates a novel
combination of features: (i) efficient, high-yielding synthetic scheme, (ii) multiple,
proximate rotators in one covalently bonded molecular system, (iii) exclusion of other
molecules and ions from the stator interior that may impede rotator motion, and (iv)
hindered rotators experiencing friction through exposure to solvent.
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Scheme 4.1. Gyroscope-inspired tribenzylamine hemicryptophane (5) possesses a rigid
stator (a and c) and three rotator groups (b). Arrows illustrate rotation but are not
intended to suggest unidirectionality.
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Gyroscope-inspired molecular systems have focused largely on approaching
barrierless rotation of isolated or sequestered rotors. One of the first examples (also
referred to as a molecular turnstile) was synthesized by Moore and Bedard (Figure
4.1a).33,34 The creative design included a rigid hexa(phenylacetylene) framework that
preserved the low barrier of rotation about the 1,4-axis of the substituted p-phenylene
moiety. Garcia-Garibay and coworkers extended these ideas in the construction of
amphidynamic crystals,11,15,35-54 where the introduction of bulky substituents creates
sufficient space in the lattice framework to allow near barrierless rotation of the central pphenylene group (Figure 4.1c). Furthermore, the p-phenylene moiety can be
functionalized to create a dipole moment that could be used for controlling motion with
an external electric field.11,36-38,42 Following a different approach, Gladysz and coworkers
prepared a series of metal-centered molecular gyroscopes in which the rotator is protected
by three-spoke structures as part of the stator (Figure 4b). The rotational dynamics of
these gyroscopes were studied in solution and their crystal structures indicated sufficient
free volume around the rotator to allow low-barrier rotation.9,55-59 Most recently,
Kitagawa et al. designed a self-assembled supramolecular gyroscope where the stator is a
heterocapsule formed by noncovalent interactions and the rotator is an encapsulated
guest.60

Herein, we report a streamlined synthesis of a gyroscope-inspired tribenzylamine
hemicryptophane (5, Scheme 4.2) involving multiple hindered rotators, where fast
rotation is observed by 1H NMR spectroscopy above a critical temperature. Rotations
about the 1,4-axis of the three p-phenylene rotators encased in a rigid CTV-
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trismethylamine stator were investigated using 1H variable temperature (VT) NMR
spectroscopy and molecular dynamics (MD) simulations.
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Scheme 4.2. Three-step synthesis of gyroscope-inspired tribenzylamine hemicryptophane
5.
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RESULTS AND DISCUSSION
Synthesis and X-ray crystal structure of hemicryptophane 5. In order to synthesize
the gyroscope-inspired tribenzylamine hemicrytophane 5, the linkers (including the
rotators) were first cyclized in the rigid CTV framework and then closed with an amine to
form the final three-dimensional structure (Scheme 2). Reaction of commercially
available vanillyl alcohol 1 and dibromo-p-xylene 2 gave the versatile linker 3 in 65%
yield. Cyclization of 3 was achieved with a catalytic amount of Sc(OTf)3 in acetonitrile to
afford the “gyroscope scaffold intermediate” 4 in 29% yield. This reaction was based on
previous protocols where various 3,4-disubstituted benzyl alcohols were treated with
catalytic Sc(OTf)3 to prepare CTV and cryptophane derivatives.18 Compound 4 was
reacted with 7 N NH3 in MeOH to give 5 in 67% yield, with an overall yield of 13% for
the three steps. Compound 5 was characterized by solution 1H NMR and

13

C NMR

spectroscopy, high-resolution mass spectrometry (using electrospray ionization method)
and X-ray crystallography. This short synthetic scheme utilizes mild conditions and
results in high overall yields. Moreover, this route provides ample versatility by
increasing the number of methylene spacer units or introducing new functional groups on
3 to form rotators with different conformations, rotation barriers, and dipole moments.
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Figure 4.2. (a) ORTEP representations for 5 with atom labels. Hydrogen atoms are
omitted for clarity. (b) Space-filling side and bottom view of 5. Atom color code: C is
gray, O is red, N is blue, and H is white. (c) Selected bond lengths (Å), angles (°) and
dihedral angles (°) of compound 5.
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The X-ray crystal structure of 5 indicates the three rotators adopt a propeller
conformation (Figure 4.2a,b). 5 crystallizes in the monoclinic space group P21/c and each
unit cell consists of four molecules with two of each enantiomer. In both enantiomers the
p-phenylene rotators are oriented edgewise into the interior (angled away from the
methoxy group ortho to them) with an average dihedral angle of ~ 88.1° for O-CbenzylicCphenyl-Cphenyl, ~ -68.6° for N-Cbenzylic-Cphenyl-Cinterior-phenyl and ~ 107.5° for N-CbenzylicCphenyl-Cexterior-phenyl (see Figure 4.2c). The minimal distance from the phenylic proton on
C44 (pointing into the cage) to the plane described by the next aryl ring (C10 to C15) is
relatively small at 3.22 Å. After the van der Waals radii for hydrogen and carbon are
included,61 the “clearance” distance is approximately 0.32 Å. The distance from the same
proton to the nitrogen atom was even shorter at 2.97 Å, with clearance distance of 0.22 Å
when van der Waals radii are included, as the nitrogen is oriented into the interior with an
average C–N–C bond angle of 114.4° (see Figure 4.2c). This propeller-shaped
conformation with a pyramidal nitrogen atom where the lone pair is pointed into the cage
is similar to the crystal structure of tribenzylamine, where the rigid CTV is not present.62
It is believed that this conformation is primarily favored due to steric hindrance.62 Despite
the propeller conformation of the rotators and the positioning of the nitrogen atom into
the interior of the cage, rotator motion is expected given the observed clearance
distances.

Unlike some previously reported porous gyroscopes,58 which encountered barriers
to rotation due to the intercalation of solvent molecules (or neighboring molecules in
solid state), the small internal volume in 5 should prevent guest encapsulation. Indeed, X-
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ray crystallography indicated an empty tribenzylamine hemicryptophane, lacking solvent
molecules. Small molecules such as helium, dihydrogen, dinitrogen and xenon were not
observed to bind to 5 at 1 atm over a range of temperatures, 47 °C to -93 °C (see
Experimental procedures section). Molecular dynamics simulations were also in
agreement with the experimental findings and suggest that these small molecular species
should be excluded from the interior (Figure 4.3).
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Figure 4.3. Molecular dynamics (MD) simulations were carried out in the absence (a)
and presence (b) of the xenon atom (OPLS63 force field parameter for Xe; ε = 0.4330 kcal
mol-1 and r = 2.20 Å) inside of 5. Using the crystal structure of 5 as the starting structure,
a 50 ns simulation, with a time step of 0.5 fs, was performed for each case in the absence
of solvent at 25 °C.64 The difference of the average potential energies with and without
xenon was 0.7 kcal mol-1, suggesting that there is no energetic stabilization in the
presence of xenon, consistent with 5 having no experimentally observed affinity for Xe.
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Computational modeling was used to explore effects due to rotation of the pphenylene rotators. GRASP65 was employed in order to investigate whether a potential
interior cavity within 5 emerges with rotation of the rotators. With a probe radius of 1.4
Å, only in improbable, high-energy structures (ΔE > 30 kcal mol-1, where ΔE is the
energy relative to the X-ray structure) where the angle of each p-phenylene rotator
increased by 90° relative to the crystal structure was a cavity identified (Figure 4.4). This
suggests that a cavity of sufficient volume to accommodate small guest molecules is
essentially nonexistent, thereby preventing the inclusion of small molecules that may
hinder p-phenylene rotation.
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Figure 4.4. Structures with different concerted orientation of the p-phenylene rotators
(α= β = γ). Crystal structure (green), 30° (cyan), 60° (magenta), 90° (yellow), 120°
(purple) and 150° (orange). Also the cavity volume values using GRASP are shown. For
clarity, hydrogens are not rendered and the high-energy structures (ΔE > 29 kcal mol-1,
where ΔE is the energy relative to the X-ray structure) are shown as thin transparent
sticks in order to illustrate their low probability.

144

1

H VT-NMR experiments with hemicryptophane 5. In order to investigate the energy

barrier of the rotators in solution phase, we performed a 1H VT-NMR study of 5 in
CD2Cl2 from -93 °C to 27 °C. The NMR spectra in Figure 4.5 indicate that the rotational
rate of the p-phenylene rotators became slow on the NMR timescale as the temperature
was decreased. At 27 °C, the four protons (labeled H2, H3, H4 and H5 in Figure 4.5a) on
each of the three rotators were split into two doublets at 6.1 ppm (average signal from H2
and H4) and 6.9 ppm (average signal from H3 and H5). Upon cooling, these doublets
became broader and the energy barrier for p-phenylene rotation was estimated from
equations (1) and (2),66 see Experimental procedures section, to be 9.2 kcal mol-1 from the
coalescence temperature (ca. -70 °C; kcoalesce ≈ 2300 Hz). As the temperature was further
reduced to -93 °C, a new pair of doublets of equal intensity (3 protons each) arose for
each doublet that coalesced. This led to splitting of the doublet for H2 and H5 and also H3
and H4, where H2 and H3 shift upfield as they are pointed into the cavity while H4 and H5
are oriented away from the cavity. The H3-H5 splitting pattern (Figure 4.5b) evidences
that p-phenylene rotation at -93 °C is slow on the NMR timescale, trot > 3 ms. Similar
temperature-dependent behavior was recently reported for a 2,3-dichlorophenylene
rotator caged within a polysilaalkane stator.67 In line with our design, the stator remained
rigid throughout the 1H VT-NMR dataset as indicated by the fact that the integration and
splitting pattern of all CTV-trismethylamine proton peaks were constant. It is also
interesting to note that protons HA1 and HA2 remained diastereotopic throughout the 1H
VT-NMR series (Figure 4.5b). All peaks were assigned by 1H-1H NOESY experiment
(Figure 4.6)
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Figure 4.5. (a) Schematic model of the molecular motion of 5. (b) 1H VT-NMR spectra
of 5 measured in CD2Cl2 with a 500 MHz spectrometer.
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Figure 4.6. 1H-1H NOESY spectrum of 5 in CDCl3 at 27 °C with 500 MHz spectrometer
to determine the assignment of protons.
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Molecular dynamics simulations. To investigate the conformational fluctuations of the
rotators and stator, MD simulations were carried out on 5 (Figure 4.7). One of the crystal
structures was used as the initial structure, and the length of the simulations was 50 ns.
Equilibration was confirmed by monitoring relaxation of structural parameters (Figure
4.7). Three dihedral angles that reflect the conformations of the rotators were selected:
(α ≡ N1-C16-C13-C14, β ≡ N1-C32-C29-C30 and γ ≡ N1-C48-C45-C44). The symmetry
of the structure yields nearly identical average values of these angles that are in
agreement with the values observed in the crystal structure: α = -72.3° ± 10°, β = -71.8°
± 10° and γ = -72.8° ± 10°; the uncertainties (fluctuations) are one standard deviation
(Figure 4.8). The MD simulations at 25 °C indicated limited fluctuations within the
structure on the nanosecond time scale (Figure 4.9), and the CTV unit that forms the
stator remains highly rigid, in agreement with the NMR results noted above. The pphenylene units are not observed to rotate and instead librate in a manner consistent with
a hindered rotor that rotates on a time scale > 100 ns. Therefore, simulations, X-ray, and
NMR structural data all agree that the propeller-shaped conformation is highly favored in
5. High temperatures were artificially employed to observe rotation in the simulations: at
527 °C, rotations of the three p-phenylenes are frequent, conformations where the
rotators are directed edgewise into the interior (similar to what is seen in the crystal
structure) are preferentially populated, and no preferred rotational direction in the three pphenylenes is observed.
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Figure 4.7. Structural information related with the equilibration of the systems for the
MD simulations. Plotted is the root mean square deviation (RMSD) for the entire system
as a function of time step. All-atom MD simulations were carried out in the absence of
solvent at 25 °C. The temperature was controlled using Langevin dynamics. The time
step of the simulations was 0.5 fs and the length of the simulations was 50 ns.
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Figure 4.8. Plots of the fluctuations in the dihedral angles involving the p-phenylene
rings in one of the enantiomers of 5 as observed in the molecular dynamics simulations.
These three dihedral angles defined as: α ≡ N1-C16-C13-C14, β ≡ N1-C32-C29-C30
and γ ≡ N1-C48-C45-C44. As mentioned in the main text, the mean and SD values are α
= -72.3° ± 10°, β = -71.8° ± 10° and γ = -72.8° ± 10°.
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Figure 4.9. Orthogonal views of 30 superimposed structures from the MD simulation of
5. The dihedral angles are indicated: α (magenta), β (cyan) and γ (yellow).
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To investigate further the p-phenylene rotation and interactions among the rotators,
the crystal structure of 5 was minimized, and the dihedral angle α was systematically
varied (Figure 4.10). The structure was then relaxed via energy minimization,
constraining the coordinates of all atoms but those in the two remaining β and γ pphenylene rings. The β-ring is essentially invariant during the rotation. The γ-ring only
rotates at most 19.7° to accommodate the 180° rotation of the α-ring. An energy barrier
arises due to the steric interaction between the α-ring and γ-ring. Interestingly, the
rotational energy barrier estimated from this simplistic and highly-constrained calculation
(~12 kcal mol-1) is consistent with the experimental value inferred from the 1H VT-NMR
experiments (~10 kcal mol-1). The modeling results suggest that, although not entirely
independent, the rotations of the α- and γ-rings are only weakly coupled.
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Figure 4.10. Minimized energy as a function of Δα, which is rotation of the α dihedral
angle relative to the energy minimized X-ray structure (gray). The crystal structure of 5
was minimized, and the angle α was varied in 10° increments, driving rotation of the αring (magenta). For each value of Δα, the structure was energy minimized, constraining
the coordinates of all atoms but those in the two remaining p-phenylene rotators: β-ring
(cyan) and γ-ring (yellow). For clarity: the CTV moiety and hydrogens are not shown;
two carbons of the α-ring are rendered black.
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CONCLUSIONS
In summary, a novel gyroscope-inspired tribenzylamine hemicryptophane 5 was
synthesized in three steps in good overall yield using mild conditions. This synthetic
route offers the possibility of preparing hemicryptophanes with multiple, proximate
rotators, where the molecular properties of the rotators can be varied by changing the
length and composition of the linkers used to cyclize the “gyroscope scaffold
intermediate” 4. The compact size of the cavity in this system helps to avoid the inclusion
of solvent and gaseous molecules that have the potential to inhibit rotation. 1H VT-NMR
data indicate a critical temperature for the onset of rotation on the sub-millisecond time
scale and a hindered, dynamic motion of these three rotators at room temperature. The
desired rigidity of the CTV stator and the rotator properties of the p-phenylenes were
corroborated by 1H VT-NMR spectroscopy and MD simulations. As a p-phenylene ring
rotates, it encounters one of the neighboring p-phenylenes, leading to a steric barrier that
hinders rotation. Rotation of the rings appears not to be strongly correlated with one
another.

The compact size and molecular motions of 5 make it a compelling initial motif from
which to engineer unidirectional, potentially coupled rotators for molecular locomotion
or transmitting torque. Towards this goal, it may be possible to introduce sterically bulky
substituents on the linkers to control the temperatures at which rotation becomes
accessible and to favor one direction of rotation. Different substituent groups can also be
introduced to create a dipole moment on the rotators, thereby allowing the use of electric
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fields to explore rapid conformational response in these systems and to control the
direction of rotation.
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EXPERIMENTAL PROCEDURES
Reagents. All reactions were carried out in oven-dried glassware under an atmosphere of
dry nitrogen. Column chromatography was performed using 60 Å porosity, 40-75 µm
particle size silica gel from Sorbent Technologies. Thin layer chromatography (TLC) was
performed using silica gel plates with UV light at 254 nm for detection. 1H NMR (360
and 500 MHz) and 13C NMR (125 MHz) spectra were acquired on Bruker DMX 360 and
AMX 500 spectrometers. Electrospray ionization (ESI) mass spectrometry was
performed in high-resolution mode on a Micromass Autospec instrument. All reagents
were commercially available and used without further purification, unless otherwise
stated.

[4-(4(bromomethyl)benzyl)oxy-3-methoxyphenyl]methanol (3). A mixture of vanillyl
alcohol 1 (2.5091 g, 16.276 mmol, 1.0 equiv.), dibromo-p-xylene 2 (6.4033 g, 24.259
mmol, 1.5 equiv.), and K2CO3 (2.2511 g, 16.288 mmol, 1.0 equiv.) dissolved in acetone
(24.0 mL, 0.786 g/ml, 18.9 g) was heated at 70 °C overnight with stirring. The reaction
solvent was removed by rotary evaporation. The resulting residue was rinsed in a
separatory funnel with a 1:1 mixture of H2O (60 mL) and CH2Cl2 (60 mL). The phases
were separated and the aqueous layer extracted three times with CH2Cl2 (100 mL). The
combined organic layer was washed once with 1 M NaOH (100 mL) and once with
saturated NaCl (100 mL). The organic layer was dried over MgSO4, filtered, and
evaporated under reduced pressure. The crude material was purified by silica gel column
chromatography (5:95 Acetone:CH2Cl2 à 20:80 Acetone:CH2Cl2) to give 3 as white
powder (3.5422 g, 65%): m.p. 86-88 °C; 1H NMR (500 MHz, CDCl3, 25 °C) δ = 7.42156

7.38 (m, 4H), 6.96 (s, 1H), 6.85-6.81 (m, 2H), 5.14 (s, 2H), 4.60 (s, 2H), 4.49 (s, 2H),
3.89 (s, 3H), 1.86 (s, 1H); 13C NMR (125 MHz, CDCl3, 25 °C) δ = 149.9, 147.6, 137.6,
137.5, 134.5, 129.4, 127.7, 119.4, 114.1, 111.1, 70.8, 65.4, 56.1, 33.36; HRMS (ESI)
calculated for C16H17BrO3 (M+Na+) 359.0259; found 359.0239.

2,7,12-Tris-(4-bromomethylbenzyloxy)-3,8,13-trimethoxy-10,15-dihydro-5H
tribenzo[a,d,g]cyclononene (4). A mixture of 3 (2.0232 g, 6.0210 mmol, 1.0 equiv.) and
Sc(OTf)3 (0.0295 g, 0.0599 mmol, 0.01 equiv.) dissolved in MeCN (5.9 mL, 0.786 g/mL,
4.7 g) was heated at 65 °C overnight with stirring. The reaction solvent was removed by
rotary evaporation. The resulting residue was extracted twice with CH2Cl2 (150 mL) and
washed three times with sat. NaCl (150 mL). The organic layer was dried over anhydrous
MgSO4, filtered, and evaporated under reduced pressure. The crude material was purified
by silica gel column chromatography (CH2Cl2 à 2:98 THF:CH2Cl2) to give 4 as white
powder (0.5571 g, 29%): m.p. 91-93 °C; 1H NMR (360 MHz, CDCl3, 25 °C) δ = 7.397.37 (m, 12H), 6.85 (s, 3H), 6.72 (s, 3H), 5.09 (s, 6H), 4.73 (d, 3H, J = 13.7 Hz), 4.50 (s,
6H), 3.76 (s, 9H), 3.50 (d, 3H, J = 13.8 Hz); 13C NMR (125 Hz, CDCl3, 25 °C) δ = 148.6,
147.2, 137.9, 137.5, 132.9, 131.9, 129.4, 127.6, 116.4, 114.0, 71.4, 56.4, 36.6, 33.3;
HRMS (ESI) calculated for C48H45Br3O6 (M+) 954.0766; found 954.0724. The NMR
spectra matched the reported literature data.68

Tribenzylamine Hemicryptophane (5). A mixture of 4 (0.0406 g, 0.0426 mmol, 1.0
equiv.) and K2CO3 (0.0869 g, 0.629 mmol, 15.0 equiv.) dissolved in MeCN (58 mL,
0.786 g/mL, 46 g) was heated at 90 °C with stirring as 7 N NH3 in MeOH (0.0711 mL of
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7 N NH3, 0.5 mmol, ~12 equiv., in 4.7 mL of MeCN) was added by a syringe pump over
8 h. The reaction solvent was removed by rotary evaporation. The resulting residue was
extracted with CH2Cl2 and transferred to a separatory funnel. The organic layer was
washed once with a 1:1 mixture of H2O (50 mL) and 1 M NaOH (50 mL) and then with 1
M NaOH (50 mL). The aqueous layer was extracted with CH2Cl2 (50 mL) and the
combined organic layer was washed with sat. NaCl (50 mL). The organic layer was dried
over anhydrous MgSO4, filtered, and evaporated under reduced pressure. The crude
material was purified by silica gel column chromatography (50:50 CH2Cl2: hexanes à
50:40:10 CH2Cl2: hexanes: EtOAc à 60:30:10 CH2Cl2: hexanes: EtOAc; all with 1%
TEA) to give 5 as a white powder (0.0206g, 67%): m.p. (decom.) > 250 °C); 1H NMR
(360 MHz, CDCl3, 25 °C) δ = 7.34 (s, 3H), 6.96-6.93 (m, 9H), 6.18 (d, 6H, J = 7.9 Hz),
5.41 (d, 3H, J = 12.1 Hz), 5.06 (d, 3H, J = 12.2 Hz), 4.83 (d, 3H, J = 13.7 Hz), 3.60 (d,
3H, J = 13.8 Hz), 3.58 (s, 9H), 3.54 (d, 3H, J = 13.2 Hz), 3.41 (d, 3H, J = 13.2 Hz); 13C
NMR (125 MHz, CDCl3, 25 °C) δ = 147.7, 143.0, 140.3, 132.9, 131.7, 130.8, 128.4,
127.4, 117.9, 113.9, 68.8, 55.5, 55.3, 34.9; HRMS (ESI) calculated for C48H45NO6
(M+H+) 732.3326; found 732.3340.
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Crystal growth and X-ray crystallography. Compound 5 was crystallized by vapor
diffusion of diethyl ether or n-pentane into toluene. It crystallizes in the monoclinic space
group P21/c (systematic absences 0k0: k = odd and h0l: l = odd) with a = 17.098(2) Å, b
3

= 11.4592(9) Å, c = 21.096(2) Å, β = 113.539(2)°, V = 3789.3(6) Å , Z = 4 and dcalc =
3

1.283 g/cm . X-ray intensity data were collected on a Rigaku Mercury CCD area
detector employing graphite-monochromated Mo-K radiation (λ = 0.71073 Å) at a
α

temperature of -130 °C. Preliminary indexing was performed from a series of twelve 0.5°
rotation images with exposures of 30 s. A total of 336 rotation images were collected
with a crystal to detector distance of 35 mm, a 2θ swing angle of -12°, rotation widths of
0.5° and exposures of 10 s: scan no. 1 was a φ-scan from 170° to 338° at ω = 0° and χ =
0°. Rotation images were processed using CrystalClear,69 producing a listing of
2

2

unaveraged F and σ(F ) values which were then passed to the CrystalStructure70
program package for further processing and structure solution on a Dell Pentium III
computer. A total of 15571 reflections were measured over the ranges 5.2 ≤ 2θ ≤ 50.02°,
-16 ≤ h ≤ 20, -13 ≤ k ≤ 12, -23 ≤ l ≤ 25 yielding 6601 unique reflections (Rint = 0.0261).
The intensity data were corrected for Lorentz and polarization effects and for absorption
using REQAB71 (minimum and maximum transmission 0.853, 1.000).

The structure was solved by direct methods (SIR97). 7 2 Refinement was by full2

matrix least squares based on F using SHELXL-97. 7 3 All reflections were used during
2

2

refinement (F values that were experimentally negative were replaced by F = 0). The
2

2

2

2

2

weighting scheme used was w = 1/[σ (F o )+ 0.0547P + 0.9350P] where P = (F o + 2F c

)/3. Non-hydrogen atoms were refined anisotropically and hydrogen atoms were refined
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using a "riding" model. Refinement converged to R1 = 0.0479 and wR2 = 0.1107 for 5502
reflections for which F > 4s(F) and R1 = 0.0599, wR2 = 0.1204 and GOF = 1.078 for all
6601 unique, non-zero reflections and 500 variables (R1 = ∑ ||Fo| - |Fc|| / ∑ |Fo|; wR2 = {∑
2

2 2

2 2 1/2

w (F o - F c ) / ∑ w(F o ) }

; GOF = {∑ w (F 2o - F 2c )2 / (n - p)}1/2 where n = the number

of reflections and p = the number of parameters refined). The maximum Δ/σ in the final
cycle of least squares was 0.001 and the two most prominent peaks in the final difference
3

Fourier were +0.173 and -0.253 e/Å .
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Calculating from 1H VT-NMR data the energy barrier for p-phenylene rotation.
Equation 1 was used to determine the p-phenylene rotation rate at the coalescence
temperature:
k=

πΔv 0

(1)

2

where k is the rate coefficient, ∆v0 = vA-vB is the chemical shift difference (in Hz)
€

between the two separate signals at slow exchange (in this case at -93 °C or 180 K). The
Arrhenius equation (2) was used to determine the activation energy, Ea, at the
coalescence temperature, T (in K):
ln(k / Hz) = −

E a ⎛ 1 ⎞
⎜ ⎟ + ln(A / Hz)
R ⎝ T ⎠

(2)

where A is the pre-exponential factor and R is the universal gas constant.66
€
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Computational methods. All-atom MD simulations were carried out using NAMD2.64
The internal bonded parameters were obtained from AMBER-9474 and the nonbonded
parameters were proposed in previous studies.75-79 Simulations were performed in the
absence of solvent at 25 °C and temperature was controlled using Langevin dynamics
with a damping coefficient of 5 ps-1. The time step of the simulations was 0.5 fs.
Relaxation calculations using energy minimization consist of up to 10,000 steps of the
conjugate gradient algorithm as implemented in NAMD2; energy was monitored to
confirm minimization.64

GRASP65 was employed to investigate a potential interior cavity within 5. Different
conformations were generated by manual rotations of the three p-phenylenes. The
rotations were systematically performed in 10° increments using one of the crystal
structures of 5 as reference. A probe radius of 1.4 Å was used for all calculations.
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1

H NMR and 129Xe NMR experiments to determine the binding of He, H2, N2 and Xe

to hemicryptophane 5
To conduct NMR experiments, 0.0005 g (0.0007 mmol) of hemicryptophane was
dissolved in 500 µL of CDCl3 or CH2Cl2 to provide a final concentration ~ 1.4 mM. In
order to determine encapsulation for He, H2 and N2, 1H NMR experiments were
performed. For Xe, a hyperpolarized 129Xe NMR spectrum was collected. For detailed
Experimental procedures for hyperpolarized 129Xe NMR spectroscopy, please refer to the
Supporting Information in Chambers et al.19 For these NMR experiments, the
hemicryptophane solution was loaded into a 5-mm stopcock-sealable NMR tube. The
samples were degassed using the freeze-pump-thaw method. The gas (e.g., He, H2, N2)
was then bubbled into the sample tube for a few minutes, sealed, shaken and allowed to
equilibrate for 1, 3, 24 and 48 h. Hyperpolarized 129Xe NMR spectra were collected in the
minutes following bubbling with hyperpolarized 129Xe.

No evidence of binding was observed for He, H2, N2 or Xe due to the absence of
spectral changes in the 1H and 129 Xe NMR spectra when each of these gases was
introduced. 1H variable temperature (VT) NMR spectroscopy was also performed for He,
H2, and N2 at temperatures ranging from -93 °C to 47 °C. None of these spectra indicated
binding even at the lowest temperature, further confirming that these gas molecules were
not encapsulated by the hemicryptophane.
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C NMR of 3 in CDCl3 at 25 °C
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CHAPTER 5: SUMMARY AND FUTURE DIRECTIONS
This thesis aimed to look at the role of cryptophanes and their derivatives in hostguest chemistry (Chapter 2),

129

Xe NMR biosensing for early cancer detection (Chapter

3), and the emerging field of molecular devices (Chapter 4).

Chapter 2 focused on the development of a new water-soluble tris(triazole)ethylamine cryptophane (TTEC) and its binding affinity for two noble gases:
xenon and radon. TTEC was determined to be the tightest xenon binder to date (KA =
42,000 M-1 at 293 K in buffer). Preliminary computational studies by Lu Gao in the
Saven lab predict that TTEC should have the strongest binding affinity for xenon, at least
in part because it has the lowest occupancy of water molecules inside the cavity (~0.5)
when compared to other anionic cryptophanes (e.g., Huber’s hexaacid cryptophanes,1
TAAC,2 and TTPC).3 Additionally, simulations showed that the other anionic
cryptophanes had a higher population of sodium counter ions around them than TTEC.
Since xenon binding requires interior water molecules and solvent cations to be
displaced, this lower occupancy of both encourages tighter binding.

TTEC also

represents the first example of a discrete molecular species binding to radon. The
radiometric binding assay developed is extremely versatile and can be used in future
studies to determine the binding affinity of a wide variety of water-soluble hosts to radon.
Since indoor accumulation of radon may cause a 5-31% increase in lung cancer risk per
100 Bq m-3 exposure,4 it is important to understand how radon binding to specific
biological molecules may lead to a higher incidence of cancer.
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The promising diagnostic applications of

129

Xe gas as a sensitive MRI contrast

agent (outlined in Chapters 1 and 3) make the development of tighter xenon binders an
important goal. Future studies could include the synthesis of water-soluble cryptophaneA or cryptophane-1.1.1. derivatives where anionic and cationic functional groups could
be incorporated at varying distances from the cryptophane core. Because a cationic
water-soluble cryptophane (TTEC) shows the highest affinity for xenon to date, this
suggests that improved Xe binding may come from incorporating cationic amine groups
closer to the cryptophane core (e.g., as in TAAC) or in a smaller host (e.g., cryptophane
1.1.1.). We have shown that the peripheral solubilizing groups can alter the entropic and
enthalpic contributions along with the overall binding affinity of the host towards xenon.
The kinetics of xenon binding are also extremely important for applications involving
ultra-sensitive hyperpolarized

129

Xe detection. These studies will be guided by

computational calculations in collaboration with the Saven lab, and include
considerations of cryptophane solvation, as well as interactions with cations and anions in
solution. Moreover, we anticipate that generating related host molecules with larger
dipole moments will lead to much higher xenon affinities. This was one motivation for
the generation of hemicryptophanes that incorporate an electron-donating amine. The
first-generation hemicryptophane of this type synthesized by our laboratory was too small
and rigid to bind Xe but had other favorable physical properties, as described in Chapter
4.
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The synthesis of cryptophanes with high binding affinities for xenon plays a
central role in our lab’s overall goal to develop

129

Xe biosensors for early cancer

detection (outlined in Chapter 3). A folate-conjugated xenon biosensor was developed in
this thesis, which was readily soluble in water and was successfully delivered to cells
overexpressing FRα. The biosensor showed a 10-fold selectivity for KB cells that
overexpressed FRα, which is currently the highest level of selectivity reported by a
cryptophane biosensor in vitro.

In an effort to synthesize a cocktail of biosensors that target a variety of medically
relevant biomarkers for multiplexing purposes, integrin αvβ3-targeting cryptophane
biosensors have been developed in our laboratory by Garry Seward.5,6 Integrin αvβ3 is an
important biomarker as it has been shown to be associated with tumor angiogenesis and
metastasis7,8 and similar to the folate receptor, it is overexpressed in a large variety of
tumor cells whereas expression is minimal in most normal tissues.9-11 To target the
integrin αvβ3 receptors, the cryptophane was conjugated to a cyclic arginine–glycine–
aspartic acid (RGD) moiety by a Huisgen [3+2] cycloaddition reaction. Additionally, to
overcome solubility issues, two propionic acid groups were added to the two remaining
propargyl groups on the cryptophane (Figure 5.1).5 The biosensor was successfully
delivered into cells and showed a 4-fold selectivity by flow cytometry towards cells
overexpressing the targeted receptor.

129

Xe NMR spectroscopy studies were performed

and the biosensor indicated a shift of 4 ppm upon binding to the targeted protein.5
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concentration.23 Biosensor 3 was similarly toxic in the noncancerous HFL-1 fibroblasts, reaching a maximum toxicity of
40% after 24 h incubation at 100 mM concentration.
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In an effort to perform similar binding experiments with the folate-conjugated
xenon biosensor,

129

Xe NMR spectroscopy methods with higher sensitivity need to be

employed. In conventional hyperpolarized

129

Xe NMR spectroscopy, most binding

studies are performed at micromolar concentrations of cryptophane biosensor, however
targets such as the folate binding protein (FBP) and integrin receptors tend to aggregate at
such concentrations, which limits the utility of this approach. In recent years, an ultrasensitive NMR technique called Hyper-CEST (hyperpolarized

129

Xe chemical exchange

saturation transfer) has been successfully utilized to detect 0.7 pM virus capsid with 125
cryptophanes attached (87 pM cryptophane equivalent).12 Hyper-CEST is a technique
that can amplify cryptophane cage-related magnetization by using a specific RF pulse
that selectively saturates the biosensor-encapsulated Xe magnetization.13 Following
chemical exchange with the free Xe in solution, a high population of depolarized nuclei is
accumulated.13 After several cycles of continuous depolarization of the cage-related
magnetization, the signal can be measured indirectly by calculating the difference
between initial and final bulk (Xe in solution) magnetization.13 Yubin Bai in our
laboratory has been working on the detection of water-soluble cryptophanes at low
concentrations using Hyper-CEST. Recently, we were able to detect TAAC at very low
concentrations (1.4 pM), which sets the new lowest detectable concentration for
cryptophanes using this technique. Therefore, the next step will involve optimizing the
Hyper-CEST conditions and using it to detect NMR resonances produced as a result of
the folate-conjugated cryptophane binding to the monomeric FBP at nanomolar or
picomolar concentrations.
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Another advancement in the use of hyperpolarized

129

Xe gas towards in vivo

applications includes the ability to perform cellular 129Xe NMR spectroscopy on a variety
of prokaryotic and eukaryotic cells.14 The cell density in these experiments ranged from
42 to 162 million cells per mL, with typically 0.5 mL sample volumes.14 The NMR
spectra of intact cells from various cell lines were shown to consist of two distinct peaks:
peak 1 at 199.5 ppm was assigned to intracellular components whereas peak 2 at 195.5
ppm was assigned to extracellular components (Figure 5.2). Such distinct peak separation
may make it possible to differentiate tumor and healthy cells by hyperpolarized

129

Xe

NMR spectroscopy due to differences in membrane flexibility or internal pH.14 Recent
studies have also focused on imaging human lungs and quantifying blood flow to human
brains using hyperpolarized 129Xe gas.15,16 Using conventional 1H MRI, lungs are difficult
to image due to low proton concentration in the airways. Such limitations make 129Xe gas
a very attractive imaging agent for lungs since it is possible to continuously replenish
hyperpolarized 129Xe gas via inhalation and breath holds.
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The ability to perform cellular NMR imaging using hyperpolarized

129

Xe gas has

also motivated the development of cryptophane-based pH biosensors in the Dmochowski
group. Intracellular pH is critical for various functions in cells such as proliferation and
apoptosis,17-21 endocytosis,18 and multidrug resistance.22 However, abnormal changes in
pH due to modifications in cellular functions, growth and division have been associated
with cancer23 and Alzheimer’s.24 Therefore, the development of 129Xe biosensors that can
clearly distinguish changes in both intra- and extracelluar pH would assist in the sensitive
detection of various diseases.

To develop such a biosensor, a recent design from our laboratory included
conjugating a GALA peptide to tripropargyl cryptophane by utilizing the Huisgen [3+2]
cycloaddition reaction. The water-soluble GALA peptide consists of 30 amino acids
(WEAALAEALAEALAEHLAEALAEALEALAA) with a repeat sequence of glutamic
acid-alanine-leucine-alanine (Figure 5.3a).25 The apolar leucines confer relatively high
hydrophobicity, the polar glutamic acids add a pH-dependent component to the
hydrophobicity and net charge while the alanine residues act as spacers between the polar
and apolar faces of the helix.25 It also contains a histidine and tryptophan residue for
NMR and fluorescence purposes. GALA is known to interact with the lipid bilayer
preferentially at acidic pH as it undergoes a coil to α-helical transition from pH 5.0 to
7.5.25 At pH 5.0, some of the glutamic acids (with carboxylate side chains) are
protonated, which promotes the formation of an α-helical coil. At pH 7.5, electrostatic
charge repulsions between the deprotonated carboxylates on the glutamic acid residues
destabilize the helix. Circular dichroism (CD) measurements performed on GALA
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indicated that the molar ellipticity at 222 nm changed dramatically from -11,500 deg cm2
dmol-1 at pH 5.1 to -4,000 deg cm2 dmol-1 at pH 7.6, which is consistent with a decrease
in helical content as the pH was increased (Figure 5.3).25 This peptide has been used in
previous studies for pH-triggered lysis of liposomes, because at pH 5.0 the liposomes
leak as GALA becomes incorporated into the vesicle bilayer and aggregates to form a
transbilayer pore.25,26

Due to xenon’s polarizability and sensitivity to molecular environment, we expect
that a GALA-conjugated cryptophane will reflect a distinct

129

Xe NMR chemical shift

due to the conformational changes in the peptide from pH 5.0 to 7.5. Figure 5.4 shows the
potential synthetic scheme for such a biosensor. If the GALA-conjugated cryptophane is
not highly water-soluble, 2-azido propionic acid groups could also be “clicked” on to
improve solubility, as was done with the integrin and carbonic anhydrase targeting
biosensors.5,27 The synthesis of this biosensor is currently underway.
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1
2

a)

b)

c)

Figure 5.3. a) Circular dichroism spectra of GALA in 5 mM TES buffer, 100 mM KCl at
varying pH, b) Structural representations of the GALA peptide with side view along the
helical axis and end view of the C-terminus. Oxygen, carbon, nitrogen, hydrogen and
sulfur atoms are represented by red, light blue, dark blue, white and yellow color,
respectively, c) Helical grid representation of GALA demonstrating the stacking of the
glutamic acid residues. Figure was adapted from Subbarao and Li, et al.25,26
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Figure 5.4. Synthetic scheme of a GALA-conjugated cryptophane pH sensor.
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As mentioned in Chapter 1, our lab has synthesized several carbonic anhydrase
(CA)-targeting

biosensors

where

the

recognition

moiety

consisted

of

a

benzenesulfonamide group attached to the cryptophane by a variable-length linker. These
biosensors exhibited the largest changes in chemical shifts upon binding to CA (3.0-7.5
ppm) and were able to differentiate between CA I and II isozymes, showing either 1 or 2
“bound” peaks.27 We hypothesized that this was due to the presence of racemic mixtures
(+/-) of enantiomers for the biosensor, which formed diastereomers once bound to the
chiral protein. In order to perform multiplexing with hyperpolarized

129

Xe MR imaging

and maintain high signal-to-noise, it is pertinent to reduce the number of NMR
resonances due to racemic mixtures. To achieve this goal, enantiomerically pure
cryptophanes are currently being synthesized by Dr. Olena Taratula in our lab. The
synthetic scheme for making enatiomerically pure cryptophanes involves the deprotection
of tri-substituted cryptophane using a Pd catalyst to afford tri-hydroxyl cryptophane
(Figure 5.5a). Tri-hydroxyl cryptophane can then be reacted with 3 equiv. (S)-Mosher’s
acid in the presence of DMAP/Et3N. The two resulting cryptophane-A diastereomers 2a
and 2b functionalized with the three chiral auxillaries are successfully separated by
column chromatography. In previous studies, in an effort to synthesize enantiomerically
pure cryptophanes, diastereomers of mono(-)camphanic ester cryptophanes had also been
synthetized which required HPLC purification for effective separation.28 Once the
diastereomers are separated using column chromatography, they can be deprotected via
basic hydrolysis affording enantiopure tri-hydroxyl cryptophanes (-) 3a and (+) 3b.
Finally, reaction with 3 equiv. propargyl bromide would give the enantiomerically pure
cryptophane (-) 4a and (+) 4b. Targeting moieties such as the benzesulfonamide group or
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folate recognition moiety can then be attached by [3+2] cycloaddition to synthesize a
variety of enantiomerically pure 129Xe cryptophane biosensors.
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a)

b)

c)

(-) 2a
(+) 2b

238

Q, mdeg
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-70
238

240

280

320

!, nm

Figure 5.5. a) Synthesis of enantiopure tripropargyl cryptophanes, b) Synthesis of future
enantiopure CA biosensors, c) Circular dichroism spectra confirming the separation of
(+) 2a and (-) 2a diastereomers by column chromatography. Figure adapted from Dr.
Olena Taratula (Personal communication).
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Lastly, in Chapter 4 we outlined a new application for a tribenzylamine
hemicryptophane where the cage could be utilized to develop molecular devices. A
tribenzylamine moiety was connected to a cyclotriveratrylene (CTV) unit to form a new
hemicryptophane, which resembled a macroscopic gyroscope. Similar to a gyroscope, it
had a stator (amine and the CTV unit) with multiple rotators (p-phenylene groups). 1H
variable temperature NMR spectroscopy and molecular dynamics simulations were in
agreement that the rotation energy barrier of the rotators was approximately 10 kcal/mol.
Currently, computational studies are underway in collaboration with the Saven group to
determine how structural changes in the cage (e.g., removal of the methoxy groups,
incorporation of different moieties with dipole moments or bulkier substituents) may alter
the rotational barrier of the p-phenylene groups. One can imagine that by engineering
hemicryptophanes with rotators that undergo unidirectional motion, it should be possible
to direct their movement in solution or on surfaces.
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APPENDIX A: X-RAY STUCTURE DETERMINATION OF
TRIBENZYLAMINE HEMICRYPTOPHANE

MeO

O
O

O

OMe

OMe

N
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Tribenzylamine hemicryptophane, C48H45NO6, crystallizes in the monoclinic
space group P21/c (systematic absences 0k0: k = odd and h0l: l = odd) with a =
3

17.098(2)Å, b = 11.4592(9)Å, c = 21.096(2)Å, β = 113.539(2)°, V = 3789.3(6)Å , Z = 4
3

and dcalc = 1.283 g/cm . X-ray intensity data were collected on a Rigaku Mercury CCD
area detector employing graphite-monochromated Mo-K radiation (λ = 0.71073 Å) at a
α

temperature of 143 K. Preliminary indexing was performed from a series of twelve 0.5°
rotation images with exposures of 30 seconds. A total of 336 rotation images were
collected with a crystal to detector distance of 35 mm, a 2θ swing angle of -12°, rotation
widths of 0.5° and exposures of 10 seconds: scan no. 1 was a φ-scan from 170° to 338° at
ω = 0° and χ = 0°. Rotation images were processed using CrystalClear,1 producing a
listing of unaveraged F

2

2

and σ(F ) values which were then passed to the

CrystalStructure2 program package for further processing and structure solution on a Dell
Pentium III computer. A total of 15571 reflections were measured over the ranges 5.2
≤2θ ≤50.02 °,

-16 ≤	
 h ≤	
 20,

-13 ≤	
 k ≤	
 12,

-23 ≤	
 l ≤	
 25 yielding 6601 unique

reflections (Rint = 0.0261). The intensity data were corrected for Lorentz and polarization
effects and for absorption using REQAB3 (minimum and maximum transmission 0.853,
1.000).

The structure was solved by direct methods (SIR97). 4 Refinement was by full2

matrix least squares based on F using SHELXL-97. 5 All reflections were used during
2

2

refinement (F ’s that were experimentally negative were replaced by F = 0). The
2

2

2

2

2

weighting scheme used was w = 1/[σ (F o )+ 0.0547P + 0.9350P] where P = (F o + 2F c

)/3. Non-hydrogen atoms were refined anisotropically and hydrogen atoms were refined
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using a "riding" model. Refinement converged to R1 = 0.0479 and wR2 = 0.1107 for 5502
reflections for which F > 4σ(F) and R1 = 0.0599, wR2 = 0.1204 and GOF = 1.078 for all
6601 unique, non-zero reflections and 500 variables.

6

The maximum Δ/σ in the final

cycle of least squares was 0.001 and the two most prominent peaks in the final difference
3

Fourier were +0.173 and -0.253 e/Å .

Table 1 lists cell information, data collection parameters, and refinement data.
Final positional and equivalent isotropic thermal parameters are given in Table 2.
Anisotropic thermal parameters are in Table 3. Tables 4 and 5 list bond distances and
bond angles. Figure 1 is an ORTEP 7 representation of the molecule with 30% probability
thermal ellipsoids displayed.
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Figure 1. ORTEP drawing of the title compound with 30% probability thermal ellipsoids.

199

Table 1. Summary of Structure Determination of Tribenzylamine Hemicryptophane
Formula:

C48H45NO6

Formula weight:

731.85

Crystal class:

monoclinic

Space group:

P21/c (#14)

Z

4

Cell constants:
a

17.098(2)Å

b

11.4592(9)Å

c

21.096(2)Å

β

113.539(2)°

V

3789.3(6)Å3

µ

0.84 cm- 1

crystal size, mm

0.40 x 0.30 x 0.15

Dcalc

1.283 g/cm3

F(000)

1552

Radiation:

Mo-K (λ = 0.71073Å)

2θ range

5.2 – 50.02°

hkl collected:

-16 ≤	
 h ≤	
 20; -13 ≤	
 k ≤	
 12;

α

-23≤	
 l ≤	
 25
No. reflections measured:

15571

No. unique reflections:

6601 (Rint = 0.0261)

No. observed reflections

5502 (F>4σ)
200

No. reflections used in refinement

6601

No. parameters

500

R indices (F>4σ)

R1 = 0.0479
wR2 = 0.1107

R indices (all data)

R1 = 0.0599
wR2 = 0.1204

GOF:

1.078

Final Difference Peaks, e/Å3

+0.173, -0.253
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Table 2. Refined Positional Parameters for Tribenzylamine Hemicryptophane

Atom

x

y

z

Ueq, Å2

C1

0.68997(11)

0.3795(2)

0.29839(9)

0.0268(4)

H1a

0.6451

0.3270

0.2672

0.036

H1b

0.7209

0.3367

0.3421

0.036

C2

0.75236(11)

0.40673(14)

0.26512(9)

0.0246(4)

C3

0.84043(11)

0.41596(14)

0.30238(9)

0.0244(4)

C4

0.89146(11)

0.4396(2)

0.26611(9)

0.0264(4)

H4

0.9515

0.4432

0.2911

0.035

C5

0.85851(11)

0.4579(2)

0.19571(9)

0.0261(4)

C6

0.77077(11)

0.4453(2)

0.15789(9)

0.0281(4)

C7

0.71970(11)

0.4191(2)

0.19298(9)

0.0273(4)

H7

0.6602

0.4092

0.1672

0.036

C8

0.65700(13)

0.4318(2)

0.04641(11)

0.0506(6)

H8a

0.6450

0.3517

0.0562

0.076

H8b

0.6468

0.4387

-0.0026

0.076

H8c

0.6196

0.4859

0.0571

0.076

C9

0.97285(11)

0.5726(2)

0.19077(10)

0.0299(4)

H9a

1.0114

0.5752

0.1661

0.040

H9b

1.0073

0.5514

0.2395

0.040

C10

0.93397(10)

0.6912(2)

0.18818(9)

0.0268(4)

C11

0.92045(10)

0.7637(2)

0.13235(9)

0.0276(4)

H11

0.9395

0.7403

0.0977

0.037

C12

0.87924(11)

0.8709(2)

0.12626(9)

0.0276(4)
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H12

0.8709

0.9197

0.0877

0.037

C13

0.85038(11)

0.9070(2)

0.17561(9)

0.0270(4)

C14

0.86559(12)

0.8350(2)

0.23278(10)

0.0329(4)

H14

0.8472

0.8591

0.2677

0.044

C15

0.90709(12)

0.7294(2)

0.23933(9)

0.0320(4)

H15

0.9175

0.6821

0.2789

0.042

C16

0.80156(11)

1.0198(2)

0.16882(10)

0.0306(4)

H16a

0.8320

1.0701

0.2094

0.041

H16b

0.7981

1.0620

0.1268

0.041

C17

0.88499(11)

0.4075(2)

0.38059(9)

0.0246(4)

H17a

0.9415

0.3704

0.3932

0.033

H17b

0.8509

0.3577

0.3984

0.033

C19

0.83844(10)

0.5756(2)

0.43743(8)

0.0236(4)

C20

0.85107(10)

0.6909(2)

0.46236(8)

0.0250(4)

H20

0.8110

0.7241

0.4780

0.033

C21

0.91926(11)

0.7572(2)

0.46494(9)

0.0246(4)

C22

0.97914(10)

0.7078(2)

0.44247(9)

0.0255(4)

C23

0.96706(11)

0.5946(2)

0.41771(9)

0.0249(4)

H23

1.0077

0.5611

0.4028

0.033

C18

0.89641(10)

0.5275(2)

0.41390(8)

0.0231(4)

C24

1.10639(11)

0.7335(2)

0.42323(10)

0.0339(5)

H24a

1.1326

0.6623

0.4485

0.051

H24b

1.1508

0.7921

0.4298

0.051

H24c

1.0770

0.7157

0.3739

0.051

C25

0.86890(11)

0.9424(2)

0.49063(9)

0.0284(4)
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H25a

0.8923

1.0113

0.5205

0.038

H25b

0.8321

0.8992

0.5088

0.038

C26

0.81656(11)

0.9819(2)

0.41791(9)

0.0271(4)

C27

0.84351(11)

1.0774(2)

0.39113(9)

0.0296(4)

H27

0.8925

1.1200

0.4199

0.039

C28

0.79946(12)

1.1112(2)

0.32269(10)

0.0303(4)

H28

0.8184

1.1773

0.3056

0.040

C29

0.72828(11)

1.0500(2)

0.27887(9)

0.0278(4)

C30

0.70048(11)

0.9553(2)

0.30603(10)

0.0299(4)

H30

0.6515

0.9127

0.2772

0.040

C31

0.74325(11)

0.9228(2)

0.37437(10)

0.0304(4)

H31

0.7225

0.8592

0.3921

0.040

C32

0.68496(12)

1.0772(2)

0.20272(9)

0.0305(4)

H32a

0.6224

1.0698

0.1872

0.041

H32b

0.6981

1.1583

0.1940

0.041

C33

0.76095(11)

0.5109(2)

0.43731(9)

0.0260(4)

H33a

0.7705

0.4260

0.4353

0.035

H33b

0.7550

0.5271

0.4813

0.035

C34

0.67860(10)

0.5436(2)

0.37776(9)

0.0249(4)

C35

0.64710(11)

0.4857(2)

0.31415(9)

0.0249(4)

C36

0.57016(11)

0.5239(2)

0.26292(9)

0.0264(4)

H36

0.5473

0.4828

0.2203

0.035

C37

0.52585(10)

0.6194(2)

0.27182(9)

0.0272(4)
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C38

0.55679(11)

0.6754(2)

0.33629(9)

0.0265(4)

C39

0.63139(11)

0.6363(2)

0.38791(9)

0.0264(4)

H39

0.6514

0.6734

0.4318

0.035

C40

0.53370(13)

0.8133(2)

0.41162(10)

0.0403(5)

H40a

0.5307

0.7524

0.4432

0.061

H40b

0.4957

0.8778

0.4109

0.061

H40c

0.5924

0.8420

0.4274

0.061

C41

0.43175(11)

0.6401(2)

0.15108(9)

0.0302(4)

H41a

0.3705

0.6548

0.1232

0.040

H41b

0.4438

0.5575

0.1446

0.040

C42

0.48468(11)

0.7182(2)

0.12638(9)

0.0281(4)

C43

0.56745(11)

0.6877(2)

0.13472(10)

0.0337(4)

H43

0.5880

0.6113

0.1497

0.045

C44

0.61975(11)

0.7673(2)

0.12146(10)

0.0337(4)

H44

0.6761

0.7452

0.1282

0.045

C45

0.59082(11)

0.8795(2)

0.09831(9)

0.0295(4)

C46

0.50707(12)

0.9073(2)

0.08574(9)

0.0318(4)

H46

0.4851

0.9817

0.0673

0.042

C47

0.45492(11)

0.8278(2)

0.09974(9)

0.0312(4)

H47

0.3978

0.8488

0.0909

0.042

C48

0.65400(12)

0.9685(2)

0.09431(9)

0.0329(4)

H48a

0.6841

0.9371

0.0665

0.044

H48b

0.6236

1.0404

0.0716

0.044

N1

0.71561(9)

0.99538(13)

0.16430(7)

0.0281(3)

O1

0.74317(8)

0.45924(12)

0.08764(6)

0.0387(3)
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O2

0.90822(8)

0.48420(11)

0.15958(6)

0.0317(3)

O3

1.04669(7)

0.77780(11)

0.44864(7)

0.0318(3)

O4

0.93840(7)

0.86765(10)

0.49263(6)

0.0281(3)

O5

0.50798(8)

0.76623(11)

0.34394(7)

0.0338(3)

O6

0.45025(7)

0.66099(11)

0.22319(6)

0.0310(3)

Ueq=1/3[U11(aa*)2+U22(bb*)2+U33(cc*)2+2U12aa*bb*cosγ+2U13aa*cc*cosβ+2U23bb*cc*
cosα]
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Table 3. Refined Thermal Parameters (U's) for Tribenzylamine Hemicryptophane

Atom

U11

U22

U33

U23

U13

U12

C1

0.0279(9)

0.0225(9)

0.0288(10) -0.0014(8)

0.0100(8)

-0.0033(8)

C2

0.0275(9)

0.0184(9)

0.0265(9)

-0.0019(7)

0.0093(8)

0.0002(7)

C3

0.0282(9)

0.0172(8)

0.0261(9)

-0.0015(7)

0.0091(8)

0.0015(7)

C4

0.0249(9)

0.0241(9)

0.0289(10) -0.0028(8)

0.0094(8)

0.0007(8)

C5

0.0291(9)

0.0229(9)

0.0291(10) -0.0021(8)

0.0145(8)

-0.0004(8)

C6

0.0316(10)

0.0286(10) 0.0219(9)

-0.0001(8)

0.0085(8)

0.0035(8)

C7

0.0238(9)

0.0255(9)

0.0281(10) -0.0039(8)

0.0054(8)

0.0000(8)

C8

0.0399(12)

0.078(2)

0.0250(11)

-0.0015(11)

0.0035(9)

-0.0016(12)

C9

0.0246(9)

0.0341(10) 0.0326(11)

0.0002(8)

0.0131(8)

-0.0025(8)

C10

0.0224(9)

0.0303(10) 0.0259(10) -0.0012(8)

0.0079(7)

-0.0033(8)

C11

0.0256(9)

0.0324(10) 0.0254(10) -0.0042(8)

0.0109(8)

-0.0063(8)

C12

0.0284(9)

0.0273(10) 0.0248(9)

-0.0006(8)

0.0084(8)

-0.0046(8)

C13

0.0228(9)

0.0278(10) 0.0286(10) -0.0013(8)

0.0085(8)

-0.0040(8)

C14

0.0383(10)

0.0351(11) 0.0293(10) -0.0006(8)

0.0177(9)

0.0025(9)

C15

0.0367(10)

0.0338(11) 0.0256(10)

0.0043(8)

0.0127(8)

0.0029(9)

C16

0.0313(10)

0.0281(10) 0.0325(10)

0.0004(8)

0.0129(8)

-0.0036(8)

C17

0.0234(9)

0.0223(9)

0.0265(10)

0.0009(7)

0.0082(7)

0.0018(7)

C19

0.0238(9)

0.0259(9)

0.0182(9)

0.0024(7)

0.0053(7)

0.0015(7)

C20

0.0243(9)

0.0284(9)

0.0209(9)

-0.0012(7)

0.0076(7)

0.0029(8)

C21

0.0281(9)

0.0221(9)

0.0196(9)

-0.0014(7)

0.0053(7)

0.0013(8)
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C22

0.0232(9)

0.0272(9)

0.0236(9)

0.0012(8)

0.0067(7)

-0.0006(8)

C23

0.0257(9)

0.0269(10)

0.0222(9)

-0.0004(7)

0.0095(7)

0.0042(8)

C18

0.0244(9)

0.0233(9)

0.0177(9)

0.0019(7)

0.0042(7)

0.0023(7)

C24

0.0291(10)

0.0342(11)

0.0416(12)

0.0006(9)

0.0174(9)

0.0017(9)

C25

0.0324(10)

0.0243(9)

0.0283(10)

-0.0015(8)

0.0118(8)

0.0049(8)

C26

0.0296(9)

0.0227(9)

0.0285(10)

-0.0024(8)

0.0112(8)

0.0042(8)

C27

0.0307(10)

0.0228(9)

0.0303(10)

-0.0025(8)

0.0069(8)

0.0002(8)

C28

0.0353(10)

0.0209(9)

0.0337(11)

0.0006(8)

0.0128(9)

0.0011(8)

C29

0.0280(9)

0.0259(10)

0.0287(10)

0.0002(8)

0.0107(8)

0.0064(8)

C30

0.0246(9)

0.0314(10)

0.0312(10)

-0.0012(8)

0.0085(8)

0.0004(8)

C31

0.0289(10)

0.0291(10)

0.0343(11)

0.0026(8)

0.0137(8)

0.0005(8)

C32

0.0317(10)

0.0273(10)

0.0299(10)

0.0008(8)

0.0098(8)

0.0059(8)

C33

0.0280(9)

0.0271(9)

0.0232(9)

0.0013(7)

0.0107(8)

0.0005(8)

C34

0.0237(9)

0.0254(9)

0.0266(10)

0.0019(7)

0.0110(8)

-0.0028(8)

C35

0.0246(9)

0.0235(9)

0.0281(10)

0.0014(8)

0.0120(8)

-0.0037(8)

C36

0.0244(9)

0.0279(9)

0.0256(10)

-0.0043(8)

0.0087(8)

-0.0046(8)

C37

0.0218(9)

0.0300(10)

0.0288(10)

0.0008(8)

0.0092(8)

-0.0030(8)

C38

0.0252(9)

0.0264(10)

0.0299(10)

-0.0024(8)

0.0132(8)

-0.0012(8)

C39

0.0262(9)

0.0281(10)

0.0252(10)

-0.0014(8)

0.0105(8)

-0.0035(8)

C40

0.0394(11)

0.0439(12)

0.0354(11)

-0.0086(9)

0.0124(9)

0.0104(10)

C41

0.0236(9)

0.0389(11)

0.0246(10)

-0.0021(8)

0.0059(8)

0.0000(8)

C42

0.0243(9)

0.0321(10)

0.0244(10)

-0.0042(8)

0.0061(8)

-0.0003(8)

C43

0.0310(10)

0.0295(10)

0.0408(11)

0.0030(9)

0.0145(9)

0.0043(8)

C44

0.0255(9)

0.0360(11)

0.0410(12)

0.0029(9)

0.0147(9)

0.0047(9)

C45

0.0308(10)

0.0331(10)

0.0230(9)

-0.0032(8)

0.0092(8)

-0.0008(8)
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C46

0.0347(10)

0.0300(10)

0.0273(10)

-0.0002(8)

0.0088(8)

0.0045(9)

C47

0.0259(9)

0.0373(11)

0.0282(10)

-0.0028(8)

0.0083(8)

0.0028(8)

C48

0.0347(10)

0.0374(11)

0.0253(10)

-0.0001(8)

0.0108(8)

-0.0035(9)

N1

0.0274(8)

0.0297(8)

0.0265(8)

-0.0033(7)

0.0102(7)

-0.0011(7)

O1

0.0343(7)

0.0554(9)

0.0230(7)

0.0001(6)

0.0079(6)

0.0007(7)

O2

0.0349(7)

0.0328(7)

0.0314(7)

-0.0047(6)

0.0173(6)

-0.0031(6)

O3

0.0306(7)

0.0292(7)

0.0399(8)

-0.0068(6)

0.0186(6)

-0.0052(6)

O4

0.0282(6)

0.0234(6)

0.0302(7)

-0.0048(5)

0.0090(5)

0.0005(5)

O5

0.0312(7)

0.0368(8)

0.0320(7)

-0.0039(6)

0.0113(6)

0.0072(6)

O6

0.0230(6)

0.0422(8)

0.0257(7)

0.0001(6)

0.0075(5)

0.0039(6)

The form of the anisotropic displacement parameter is:
exp[-2π2(a*2U11h2+b*2U22k2+c*2U33l2+ 2b*c*U23kl+2a*c*U13hl+2a*b*U12hk)].
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Table 4. Bond Distances in Tribenzylamine Hemicryptophane, Å

C1-C35

1.524(2)

C1-C2

1.525(2)

C2-C3

1.397(2)

C2-C7

1.403(2)

C3-C4

1.398(2)

C3-C17

1.519(2)

C4-C5

1.378(2)

C5-O2

1.383(2)

C5-C6

1.397(2)

C6-O1

1.373(2)

C6-C7

1.384(3)

C8-O1

1.415(2)

C9-O2

1.449(2)

C9-C10

1.505(3)

C10-C11

1.383(2)

C10-C15

1.401(2)

C11-C12

1.396(3)

C12-C13

1.381(3)

C13-C14

1.397(3)

C13-C16

1.514(3)

C14-C15

1.382(3)

C16-N1

1.461(2)

C17-C18

1.521(2)

C19-C18

1.388(2)

C19-C20

1.406(2)

C19-C33

1.517(2)

C20-C21

1.374(2)

C21-O4

1.378(2)

C21-C22

1.408(2)

C22-O3

1.369(2)

C22-C23

1.383(2)

C23-C18

1.407(2)

C24-O3

1.423(2)

C25-O4

1.452(2)

C25-C26

1.504(2)

C26-C27

1.392(3)

C26-C31

1.398(3)

C27-C28

1.390(3)

C28-C29

1.389(3)

C29-C30

1.396(3)

C29-C32

1.509(2)

C30-C31

1.382(3)

C32-N1

1.466(2)

C33-C34

1.512(2)

C34-C35

1.398(2)

C34-C39

1.401(2)

C35-C36

1.398(2)

C36-C37

1.386(2)

C37-O6

1.375(2)

C37-C38

1.402(2)

C38-C39

1.380(2)

C38-O5

1.383(2)

C40-O5

1.422(2)

C41-O6

1.445(2)

C41-C42

1.506(3)

C42-C47

1.387(3)

C42-C43

1.399(2)

C43-C44

1.381(3)

C44-C45

1.394(3)

C45-C46

1.385(3)

C45-C48

1.512(3)

C46-C47

1.387(3)

C48-N1

1.464(2)

210

Table 5. Bond Angles in Tribenzylamine Hemicryptophane, °

C35-C1-C2

115.01(14)

C3-C2-C7

118.4(2)

C3-C2-C1

123.5(2)

C7-C2-C1

118.1(2)

C2-C3-C4

118.4(2)

C2-C3-C17

124.5(2)

C4-C3-C17

117.1(2)

C5-C4-C3

122.9(2)

C4-C5-O2

123.4(2)

C4-C5-C6

118.9(2)

O2-C5-C6

117.6(2)

O1-C6-C7

125.7(2)

O1-C6-C5

115.6(2)

C7-C6-C5

118.7(2)

C6-C7-C2

122.6(2)

O2-C9-C10

111.67(14)

C11-C10-C15

118.3(2)

C11-C10-C9

119.7(2)

C15-C10-C9

122.0(2)

C10-C11-C12

120.9(2)

C13-C12-C11

120.8(2)

C12-C13-C14

118.4(2)

C12-C13-C16

122.2(2)

C14-C13-C16

119.4(2)

C15-C14-C13

121.0(2)

C14-C15-C10

120.6(2)

N1-C16-C13

110.18(14)

C3-C17-C18

111.11(13)

C18-C19-C20

118.8(2)

C18-C19-C33

123.6(2)

C20-C19-C33

117.6(2)

C21-C20-C19

122.3(2)

C20-C21-O4

125.4(2)

C20-C21-C22

118.9(2)

O4-C21-C22

115.5(2)

O3-C22-C23

125.4(2)

O3-C22-C21

115.6(2)

C23-C22-C21

119.1(2)

C22-C23-C18

122.0(2)

C19-C18-C23

118.8(2)

C19-C18-C17

123.1(2)

C23-C18-C17

118.0(2)

O4-C25-C26

110.73(14)

C27-C26-C31

118.0(2)

C27-C26-C25

119.5(2)

C31-C26-C25

122.4(2)

C28-C27-C26

120.7(2)

C29-C28-C27

121.2(2)

C28-C29-C30

118.1(2)

C28-C29-C32

122.1(2)

C30-C29-C32

119.7(2)

C31-C30-C29

120.8(2)

C30-C31-C26

121.1(2)

N1-C32-C29

108.93(14)

C34-C33-C19

113.77(14)

C35-C34-C39

118.8(2)

C35-C34-C33

123.6(2)

C39-C34-C33

117.6(2)

C34-C35-C36

118.5(2)

C34-C35-C1

123.6(2)

C36-C35-C1

117.9(2)

C37-C36-C35

122.6(2)

O6-C37-C36

125.1(2)

O6-C37-C38

116.3(2)

C36-C37-C38

118.5(2)

C39-C38-O5

124.3(2)

C39-C38-C37

119.2(2)

O5-C38-C37

116.5(2)

C38-C39-C34

122.2(2)

O6-C41-C42

110.92(14)

C47-C42-C43

117.8(2)

C47-C42-C41

120.3(2)

C43-C42-C41

121.8(2)

C44-C43-C42

121.0(2)

C43-C44-C45

120.8(2)
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C46-C45-C44

118.3(2)

C46-C45-C48

122.7(2)

C44-C45-C48

118.7(2)

C45-C46-C47

120.8(2)

C46-C47-C42

121.2(2)

N1-C48-C45

109.15(14)

C16-N1-C48

113.96(14)

C16-N1-C32

114.45(14)

C48-N1-C32

114.84(14)

C6-O1-C8

117.5(2)

C5-O2-C9

115.31(13)

C22-O3-C24

117.39(14)

C21-O4-C25

118.46(13)

C38-O5-C40

116.32(14)

C37-O6-C41

118.26(13)
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